BXD Phenotypes

Pheno ID Record ID Label Category
X3063 12890 Activity of 13-week old females, total counts of fine movements and ambulatory activity [counts/unit time] Activity
X3352 12960 Activity of 13-week old males, total counts of fine movements and ambulatory activity [counts/unit time] Activity
X1093 15698 Activity (ambulations) at night, metabolic cage, chow diet, males [AUC] Activity
X2256 15699 Activity (ambulations) at night, metabolic cage, high fat diet, males [AUC] Activity
X830 17629 Activity (movement) at dark phase (night) _CD, males [AUC] Activity
X1516 17630 Activity (movement) at dark phase (night) _HFD, males [AUC] Activity
X2451 17631 Activity (rearing) at night _CD, males [AUC] Activity
X3938 17632 Activity (rearing) at night _HFD, males [AUC] Activity
X1892 17713 Activity (movement) during full day (24 hours), _CD, males [counts/hour] Activity
X908 17714 Activity (movement) during full day (24 hours), _HFD, males [counts/hour] Activity
X2130 17715 Activity (movement) during light phase (day), _CD, males [counts/hour] Activity
X2410 17716 Activity (movement) during light phase (day), _HFD, males [counts/hour] Activity
X1869 17717 Activity (movement) during dark phase (night), _CD, males [counts/hour] Activity
X1361 17718 Activity (movement) during dark phase (night), _HFD, males [counts/hour] Activity
X2500 17719 Activity (rearing) during full day (24 hours), _CD, males [counts/hour] Activity
X1574 17720 Activity (rearing) during full day (24 hours), _HFD, males [counts/hour] Activity
X4361 17721 Activity (rearing) during light phase (day), _CD, males [counts/hour] Activity
X2840 17722 Activity (rearing) during light phase (day), _HFD, males [counts/hour] Activity
X1281 17723 Activity (rearing) during dark phase (night), _CD, males [counts/hour] Activity
X1154 17724 Activity (rearing) during dark phase (night) _HFD, males [counts/hour] Activity
X1146 17733 Run distance untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [m] Activity
X2100 17734 Run distance untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [m] Activity
X712 17735 Run distance trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [m] Activity
X768 17736 Run distance trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [m] Activity
X2736 17737 Run distance improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [m] Activity
X1290 17738 Run distance improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [m] Activity
X1964 17761 Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_CD, males [km] Activity
X1927 17762 Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_CD, males [km] Activity
X1972 17763 Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_HFD, males [km] Activity
X453 17764 Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_CD, males [km] Activity
X1056 17765 Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_HFD, males [km] Activity
X299 17766 Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_HFD, males [km] Activity
X379 10285 Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males and females [cm] Anxiety
X370 10331 Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males [cm] Anxiety
X4573 10332 Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for females [cm] Anxiety
X376 10505 Open-field activity following saline injection [number of crossings during 3 min] Anxiety
X3851 10896 Anxiety assay, closed arm entries in an elevated plus maze test [n] Anxiety
X2491 10898 Anxiety assay, open arm entries in an elevated plus maze test [n] Anxiety
X1253 10904 Anxiety assay, locomotion in the light compartment relative to total in a light-dark test [%] Anxiety
X910 10905 Anxiety assay, time in the center of an elevated plus maze [sec] Anxiety
X2119 10906 Novel open field behavior, time in the field center [sec] Anxiety
X4147 10907 Anxiety assay, percentage of time in light compartment of a light-dark test [%] Anxiety
X1020 10908 Anxiety assay, percentage of time in open arms of an elevated plus maze [%] Anxiety
X5021 10909 Anxiety assay, arm entries (total) in an elevated plus maze [n] Anxiety
X4155 10910 Novel open field behavior, locomotion from 0-30 min [cm] Anxiety
X288 10911 Novel open field behavior, locomotion from 0-5 min [cm] Anxiety
X3096 10912 Novel open field behavior, locomotion from 10-15 min [cm] Anxiety
X4398 10913 Novel open field behavior, locomotion from 15-20 min [cm] Anxiety
X4526 10914 Novel open field behavior, locomotion from 20-25 min [cm] Anxiety
X4397 10915 Novel open field behavior, locomotion from 25-30 min [cm] Anxiety
X4332 10916 Novel open field behavior, locomotion from 5-10 min [cm] Anxiety
X3300 10917 Anxiety assay, transitions between light and dark compartments in light/dark test [n] Anxiety
X2750 10955 Anxiety assay (S5_PDT), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent distance traveled in light side using a light-dark box in 8-12 week-old males during 5 min session [%] Anxiety
X383 10957 Anxiety assay (S5_TLA) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), distance traveled in light-dark box by 8-12 week-old males during a 5 min session [cm] Anxiety
X730 10960 Anxiety assay (S5_NT) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), entries into light side of light-dark box by 8-12 week-old males during a 5 min session [n] Anxiety
X2449 10961 Anxiety assay (S5_NR) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), rearing events in the light side using a light-dark box in 8-12 week-old males during a 5 min session [n] Anxiety
X187 10964 Anxiety assay (E5_PDT), after restraint stress (15 min) with ethanol treatment (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 5 min session Anxiety
X1081 10966 Anxiety assay (E5_TLA) following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), locomotor activity in light-dark box by 8-12 week-old males during a 5 min session [cm] Anxiety
X2880 10969 Anxiety level following restraint stress (15 min) and ethanol treatment (1.8 g/kg i.p., E5 NT group) measured as the number of entries into light side of light-dark box in 8-12 week-old males (5 min session) Anxiety
X3717 10970 Anxiety assay following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 5 min session [n] Anxiety
X982 10973 Anxiety assay following restraint stress (15 min) and saline injection (0.018 ml/g ip), percent distance in light side using a light-dark box by 8-12 week-old males during 10 min session [%] Anxiety
X493 10975 Anxiety assay (S10_TLA), restraint stress (15 min) and saline treated (0.018 ml/g ip), distance traveled in light-dark box, 8-12 week-old males during a 10 min session [cm] Anxiety
X428 10978 Anxiety assay (S10_NT), entries into light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during a 10 min test [n] Anxiety
X2291 10979 Anxiety assay after restraint stress (15 min) and a saline injection (0.018 ml/g ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] Anxiety
X398 10982 Anxiety assay (E10_PDT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 10 min session [%] Anxiety
X433 10984 Anxiety assay (E10_TLA), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), total distance traveled in light-dark box, using 8-12 week-old males during 10 min session [cm] Anxiety
X1793 10987 Anxiety assay (E10_NT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of entries into light side of light-dark box, using 8-12 week-old males during a 10 min session [n] Anxiety
X4646 10988 Anxiety assay after restraint stress (15 min) and an ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] Anxiety
X3095 11012 Anxiety assay, time in open arm of elevated plus maze in young adult males and females [sec] Anxiety
X4739 11013 Anxiety assay, number of closed arm entries using elevated plus maze [n] Anxiety
X3186 11014 Locomotor activity, distance, open field behavior [cm] Anxiety
X4514 11015 Anxiety assay, open field behavior, duration in center of field [sec] Anxiety
X1074 11341 Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [n beam breaks] Anxiety
X3456 11342 Novel open field behavior, locomotion in the periphery from 15-30 min for males in the morphine test battery [n beam breaks] Anxiety
X2888 11343 Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [n beam breaks] Anxiety
X3007 11344 Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [n beam breaks] Anxiety
X1438 11345 Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [cm] Anxiety
X3241 11346 Novel open field behavior, locomotion locomotion in the periphery from 15-30 min for males in the morphine test battery [cm] Anxiety
X3465 11347 Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [cm] Anxiety
X2197 11348 Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [cm] Anxiety
X1070 11349 Novel open field behavior, vertical activity (rears) from 0-15 min for males [n beam breaks] Anxiety
X355 11350 Novel open field behavior, vertical activity (rears) from 15-30 min for males [n beam breaks] Anxiety
X256 11351 Novel open field behavior, vertical activity (rears) from 30-45 min for males [n beam breaks] Anxiety
X245 11352 Novel open field behavior, vertical activity (rears) from 45-60 min for males [n beam breaks] Anxiety
X2452 11353 Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] Anxiety
X2855 11354 Novel open field behavior, locomotion in the center from 0-60 min for males [cm] Anxiety
X219 11355 Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males [n beam breaks] Anxiety
X2629 11363 Novel open field behavior, urinations for males [n/test period] Anxiety
X2383 11385 Anxiety assay, time in dark side of a light-dark box for males [sec] Anxiety
X3331 11387 Anxiety assay, locomotion in the light compartment of a light-dark box for males [cm] Anxiety
X2384 11388 Anxiety assay, time in light side of a light-dark box for males [sec] Anxiety
X1882 11389 Anxiety assay, percentage of locomotion in light side of a light-dark box for males [%] Anxiety
X2390 11390 Anxiety assay, percentage of time in light side of a light-dark box for males [%] Anxiety
X2043 11391 Anxiety assay, transitions between light and dark sides of a light-dark box for males [n] Anxiety
X1248 11404 Open field behavior, percentage of distance in the center for males [%] Anxiety
X1991 11405 Open field behavior, percentage of time in center for males [%] Anxiety
X4313 11406 Open field behavior, time in corners for males [min] Anxiety
X1791 11407 Open field behavior, locomotion from 0-5 min for males [cm] Anxiety
X2290 11408 Open field behavior, locomotion from 10-15 min for males [cm] Anxiety
X1740 11409 Open field behavior, locomotion from 15-20 min for males [cm] Anxiety
X4442 11410 Open field behavior, locomotion from 5-10 min for males [cm] Anxiety
X1160 11411 Open field activity, habituation ratio for males (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] Anxiety
X2360 11412 Open field behavior, percentage time in perimeter minus time in corners for males [%] Anxiety
X3955 11413 Open field behavior, vertical activity (rears) from 0-20 min for males [n beam breaks] Anxiety
X3172 11414 Open field behavior, vertical activity (rears) from 0-5 min for males [n beam breaks] Anxiety
X2563 11415 Open field behavior, vertical activity (rears) 10-15 min for males [n beam breaks] Anxiety
X2202 11416 Open field behavior, vertical activity (rears) from 15-20 min for males [n beam breaks] Anxiety
X4181 11417 Open field behavior, vertical activity (rears) from 5-10 min for males [n beam breaks] Anxiety
X2683 11418 Open field behavior, locomotion for entire test period for males [cm] Anxiety
X1249 11419 Open field behavior, percentage of distance in the perimeter for males [%] Anxiety
X1990 11420 Open field behavior, percentage of time in perimeter for males [%] Anxiety
X1053 11434 Anxiety assay, entries in closed quadrants of a zero maze for males [n] Anxiety
X1031 11435 Anxiety assay, entries in open quadrants of a zero maze for males [n] Anxiety
X4508 11437 Anxiety assay, percentage of time in open quadrants of a zero maze for males [%] Anxiety
X4639 11438 Anxiety assay, time in closed quadrants of a zero maze for males [sec] Anxiety
X4640 11439 Anxiety assay, time in open quadrants of a zero maze for males [sec] Anxiety
X3859 11454 Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males [n] Anxiety
X4966 11455 Anxiety assay, untreated baseline, entries into open arms of a plus maze for males [n] Anxiety
X2547 11456 Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males [%] Anxiety
X4036 11457 Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males [%] Anxiety
X3728 11458 Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males [%] Anxiety
X3814 11459 Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for males [%] Anxiety
X3727 11466 Anxiety assay, time in closed arms of an elevated plus maze for males [sec] Anxiety
X3531 11467 Anxiety assay, time in middle of an elevated plus maze for males [sec] Anxiety
X3818 11468 Anxiety assay, time in open arms of a plus maze for males [sec] Anxiety
X2918 11500 Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] Anxiety
X3192 11501 Novel open field behavior, locomotion in the center from 0-60 min for males [cm] Anxiety
X1529 11502 Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males [n beam breaks] Anxiety
X3290 11506 Novel open field behavior, locomotion in the center from 0-15 min for males [n beam breaks] Anxiety
X2641 11507 Novel open field behavior, locomotion in the center from 15-30 min for males [n beam breaks] Anxiety
X2314 11508 Novel open field behavior, locomotion in the center from 30-45 min for males [n beam breaks] Anxiety
X2676 11509 Novel open field behavior, locomotion in the center from 45-60 min for males [n beam breaks] Anxiety
X3144 11510 Novel open field behavior, locomotion in the center from 0-15 min for males [cm] Anxiety
X2916 11511 Novel open field behavior, locomotion in the center from 15-30 min for males [cm] Anxiety
X2698 11512 Novel open field behavior, locomotion in the center from 30-45 min for males [cm] Anxiety
X2943 11513 Novel open field behavior, locomotion in the center from 45-60 min for males [cm] Anxiety
X1605 11514 Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males [n beam breaks] Anxiety
X1378 11515 Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males [n beam breaks] Anxiety
X2337 11516 Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males [n beam breaks] Anxiety
X3329 11517 Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males [n beam breaks] Anxiety
X4019 11518 Novel open field behavior, locomotion in the periphery from 0-15 min for males in the cocaine test battery [n beam breaks] Anxiety
X2605 11519 Novel open field behavior, locomotion in the periphery from 15-30 min for males in the cocaine test battery [n beam breaks] Anxiety
X2506 11520 Novel open field behavior, locomotion in the periphery from 30-45 min for males in the cocaine test battery [n beam breaks] Anxiety
X3341 11521 Novel open field behavior, locomotion in the periphery from 45-60 min for males in the cocaine test battery [n beam breaks] Anxiety
X3857 11522 Novel open field behavior, locomotion from 0-15 min in the periphery for males in the cocaine test battery [cm] Anxiety
X2422 11523 Novel open field behavior, locomotion from 15-30 min in the periphery for males in the cocaine test battery [cm] Anxiety
X3246 11524 Novel open field behavior, locomotion from 30-45 min in the periphery for males in the cocaine test battery [cm] Anxiety
X3917 11525 Novel open field behavior, locomotion from 45-60 min in the periphery for males in the cocaine test battery [cm] Anxiety
X1019 11526 Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males [n beam breaks] Anxiety
X1729 11527 Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males [n beam breaks] Anxiety
X1423 11528 Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males [n beam breaks] Anxiety
X2162 11529 Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males [n beam breaks] Anxiety
X1151 11530 Novel open field behavior, percentage of locomotion in the periphery for males [%] Anxiety
X3311 11531 Novel open field behavior, locomotion in the periphery from 0-60 min for males [n beam breaks] Anxiety
X2857 11532 Novel open field behavior, locomotion in the periphery from 0-60 min for males [cm] Anxiety
X1161 11533 Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males [n beam breaks] Anxiety
X2481 11553 Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] Anxiety
X2386 11554 Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [cm] Anxiety
X1134 11555 Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] Anxiety
X1836 11598 Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [n beam breaks] Anxiety
X984 11599 Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [n beam breaks] Anxiety
X682 11600 Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [n beam breaks] Anxiety
X320 11601 Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [n beam breaks] Anxiety
X1266 11602 Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [cm] Anxiety
X529 11603 Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [cm] Anxiety
X470 11604 Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [cm] Anxiety
X235 11605 Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [cm] Anxiety
X262 11606 Novel open field behavior, vertical activity (rears) from 0-15 for females [n beam breaks] Anxiety
X316 11607 Novel open field behavior, vertical activity (rears) from 15-30 min for females [n beam breaks] Anxiety
X377 11608 Novel open field behavior, vertical activity (rears) from 30-45 min for females [n beam breaks] Anxiety
X277 11609 Novel open field behavior, vertical activity (rears) from 45-60 min for females [n beam breaks] Anxiety
X890 11610 Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] Anxiety
X451 11611 Novel open field behavior, locomotion in the center from 0-60 min for females [cm] Anxiety
X1873 10204 TRBV4+ T cell levels among CD8+ T cells in spleen [%] Immune
X271 11612 Novel open field behavior, vertical activity (rears) in the center from 0-60 min for females [n beam breaks] Anxiety
X995 11620 Novel open field behavior, urinations for females [n/test period] Anxiety
X3155 11642 Anxiety assay, time in dark side of a light-dark box for females [sec] Anxiety
X4333 11644 Anxiety assay, locomotion in the light compartment of a light-dark box for females [cm] Anxiety
X3156 11645 Anxiety assay, time in light side of a light-dark box for females [sec] Anxiety
X2514 11646 Anxiety assay, percentage of locomotion in light side of a light-dark box for females [%] Anxiety
X3308 11647 Anxiety assay, percentage of time in the light side of a light-dark box for females [%] Anxiety
X1978 11648 Anxiety assay, transitions between light and dark sides of a light-dark box for females [n] Anxiety
X4691 11661 Open field behavior, percentage of distance in the center for females [%] Anxiety
X4570 11662 Open field behavior, percentage of time in center for females [%] Anxiety
X4768 11663 Open field behavior, time in corners for females [min] Anxiety
X2978 11664 Open field behavior, locomotion from 0-5 min for females [cm] Anxiety
X1324 11665 Open field behavior, locomotion from 10-15 min for females [cm] Anxiety
X703 11666 Open field behavior, locomotion from 15-20 min for females [cm] Anxiety
X2129 11667 Open field behavior locomotion from 5-10 min for females [cm] Anxiety
X2795 11668 Open field activity, habituation ratio for females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] Anxiety
X4622 11669 Open field behavior, percentage time in perimeter minus time in corners for females [%] Anxiety
X2745 11670 Open field behavior, vertical activity (rears) from 0-20 min for females [n beam breaks] Anxiety
X2254 11671 Open field behavior, vertical activity (rears) from 0-5 min for females [n beam breaks] Anxiety
X3729 11672 Open field behavior, vertical activity (rears) from 10-15 min for females [n beam breaks] Anxiety
X2554 11673 Open field behavior, vertical activity (rears) from 15-20 min for females [n beam breaks] Anxiety
X1471 11674 Open field behavior, vertical activity (rears) from 5-10 min for females [n beam breaks] Anxiety
X2139 11675 Open field behavior, locomotion for entire test period for females [cm] Anxiety
X4692 11676 Open field behavior, percentage distance in the perimeter for females [%] Anxiety
X4569 11677 Open field behavior, percentage of time in perimeter for females [%] Anxiety
X2859 11691 Anxiety assay, entries in closed quadrants of a zero maze for females [n] Anxiety
X2836 11692 Anxiety assay, entries into open quadrants of a zero maze for females [n] Anxiety
X1800 11694 Anxiety assay, percentage time in open quadrants of a zero maze for females [%] Anxiety
X1753 11695 Anxiety assay, time in closed quadrants of a zero maze for females [sec] Anxiety
X1754 11696 Anxiety assay, time in open quadrants of a zero maze for females [sec] Anxiety
X2487 11711 Anxiety assay, untreated baseline, entries into closed arms of a plus maze for females [n] Anxiety
X2441 11712 Anxiety assay, untreated baseline, entries into open arms of a plus maze for females [n] Anxiety
X1779 11713 Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for females [%] Anxiety
X3102 11714 Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for females [%] Anxiety
X726 11715 Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for females [%] Anxiety
X2321 11716 Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for females [%] Anxiety
X727 11723 Anxiety assay, time in closed arms of an elevated plus maze for females [sec] Anxiety
X1905 11724 Anxiety assay, time in middle of an elevated plus maze for females [sec] Anxiety
X1221 11725 Anxiety assay, time in open arms of an elevated plus maze for females [sec] Anxiety
X2168 11757 Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] Anxiety
X1686 11758 Novel open field behavior, locomotion in the center from 0-60 min for females [cm] Anxiety
X471 11759 Novel open field behavior, vertical activity (rears) from 0-60 min in the center for females [n beam breaks] Anxiety
X797 11763 Novel open field behavior, locomotion in the center from 0-15 min for females [n beam breaks] Anxiety
X2267 11764 Novel open field behavior, locomotion in the center from 15-30 min for females [n beam breaks] Anxiety
X2939 11765 Novel open field behavior, locomotion in the center from 30-45 min for females [n beam breaks] Anxiety
X2756 11766 Novel open field behavior, locomotion in the center from 45-60 min for females [n beam breaks] Anxiety
X1310 11767 Novel open field behavior, locomotion in the center from 0-15 min for females [cm] Anxiety
X1343 11768 Novel open field behavior, locomotion in the center from 15-30 min for females [cm] Anxiety
X2590 11769 Novel open field behavior, locomotion in the center from 30-45 min for females [cm] Anxiety
X2803 11770 Novel open field behavior, locomotion in the center from 45-60 min for females [cm] Anxiety
X944 11771 Novel open field behavior, vertical activity (rears) from 0-15 min in the center for females [n beam breaks] Anxiety
X371 11772 Novel open field behavior, vertical activity (rears) from15-30 min in the center for females [n beam breaks] Anxiety
X620 11773 Novel open field behavior, vertical activity (rears) from 30-45 min in the center for females [n beam breaks] Anxiety
X1777 11774 Novel open field behavior, vertical activity (rears) from 45-60 min in the center for females [n beam breaks] Anxiety
X1733 11775 Novel open field behavior, locomotion in the periphery from 0-15 min for females in the cocaine test battery [n beam breaks] Anxiety
X3307 11776 Novel open field behavior, locomotion in the periphery from 15-30 min for females in the cocaine test battery [n beam breaks] Anxiety
X3512 12542 Iron level of plasma of 120-day-old females fed 3 ppm Fe diet [ug/dL] Hematology
X2541 11777 Novel open field behavior, locomotion in the periphery from 30-45 min for females in the cocaine test battery [n beam breaks] Anxiety
X3430 11778 Novel open field behavior, locomotion in the periphery from 45-60 min for females in the cocaine test battery [n beam breaks] Anxiety
X3037 11780 Novel open field behavior, locomotion from 15-30 min in the periphery for females in the cocaine test battery [cm] Anxiety
X3072 11781 Novel open field behavior, locomotion from 30-45 min in the periphery for females in the cocaine test battery [cm] Anxiety
X3893 11782 Novel open field behavior, locomotion from 45-60 min in the periphery for females in the cocaine test battery [cm] Anxiety
X472 11783 Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for females [n beam breaks] Anxiety
X401 11784 Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for females [n beam breaks] Anxiety
X385 11785 Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for females [n beam breaks] Anxiety
X276 11786 Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for females [n beam breaks] Anxiety
X3377 11787 Novel open field behavior, percentage of locomotion in the periphery for females [%] Anxiety
X3304 11788 Novel open field behavior, locomotion in the periphery from 0-60 min for females [n beam breaks] Anxiety
X3183 11789 Novel open field behavior, locomotion in the periphery from 0-60 min for females [cm] Anxiety
X253 11790 Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for females [n beam breaks] Anxiety
X1569 11810 Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] Anxiety
X1391 11811 Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [cm] Anxiety
X168 11812 Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] Anxiety
X3460 11855 Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [n beam breaks] Anxiety
X2182 11856 Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the morphine test battery [n beam breaks] Anxiety
X1050 11857 Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [n beam breaks] Anxiety
X467 11858 Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [n beam breaks] Anxiety
X2944 11859 Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [cm] Anxiety
X1385 11860 Novel open field behavior, locomotion locomotion in the periphery from 15-30 for males and females in the morphine test battery [cm] Anxiety
X1468 15570 Kramer RM, Lamkin T, and colleagues TAFI15 Immune
X673 11861 Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [cm] Anxiety
X325 11862 Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [cm] Anxiety
X326 11863 Novel open field behavior,vertical activity (rears) from 0-15 min for males and females [n beam breaks] Anxiety
X238 11864 Novel open field behavior, vertical activity (rears) from 15-30 min for males and females [n beam breaks] Anxiety
X191 11865 Novel open field behavior, vertical activity (rears) from min 30-45 for males and females [n beam breaks] Anxiety
X177 11866 Novel open field behavior, vertical activity (rears) from 45-60 min for males and females [n beam breaks] Anxiety
X1413 11867 Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] Anxiety
X799 11868 Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] Anxiety
X186 11869 Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males and females [n beam breaks] Anxiety
X2669 11877 Novel open field behavior, urinations for males and females [n/test period] Anxiety
X3871 11899 Anxiety assay, time in dark side of a light-dark box for males and females [sec] Anxiety
X4308 11901 Anxiety assay, locomotion in the light compartment of a light-dark box for males and females [cm] Anxiety
X3872 11902 Anxiety assay, time in light side of a light-dark box for males and females [sec] Anxiety
X1899 11903 Anxiety assay, percentage of locomotion in light side of a light-dark box for males and females [%] Anxiety
X3931 11904 Anxiety assay, percentage time in light side of a light-dark box for males and females [%] Anxiety
X1948 11905 Anxiety assay, transitions between light and dark sides of a light-dark box for males and females [n] Anxiety
X2597 11918 Open field behavior, percentage of distance in the center for males and females [%] Anxiety
X2014 11919 Open field behavior, percentage of time in center for males and females [%] Anxiety
X3648 11920 Open field behavior, time in corners for males and females [min] Anxiety
X3571 11921 Open field behavior, locomotion from 0-5 min for males and females [cm] Anxiety
X2990 11922 Open field behavior, locomotion from 10-15 min for males and females [cm] Anxiety
X1752 11923 Open field behavior, locomotion from 15-20 min for males and females [cm] Anxiety
X4190 11924 Open field behavior, locomotion from 5-10 min for males and females [cm] Anxiety
X2700 11925 Open field activity, habituation ratio for males and females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] Anxiety
X3461 11926 Open field behavior, percentage of time in perimeter minus time in corners for males and females [%] Anxiety
X2549 11927 Open field behavior, vertical activity (rears) from 0-20 min for males and females [n beam breaks] Anxiety
X2322 10205 TRBV4+ T cell levels among CD8+ T cells in peripheral blood [%] Immune
X2667 11928 Open field behavior, vertical activity (rears) from 0-5 min for males and females [n beam breaks] Anxiety
X3336 11929 Open field behavior, vertical activity (rears) from 10-15 min for males and females [n beam breaks] Anxiety
X2405 11930 Open field behavior, vertical activity (rears) from 15-20 min for males and females [n beam breaks] Anxiety
X2934 11931 Open field behavior, vertical activity (rears) from 5-10 min for males and females [n beam breaks] Anxiety
X2819 11932 Open field behavior, locomotion for entire test period for males and females [cm] Anxiety
X2596 11933 Open field behavior, percentage of distance in the perimeter for males and females [%] Anxiety
X2015 11934 Open field behavior, percentage of time in perimeter for males and females [%] Anxiety
X1372 11948 Anxiety assay, entries in closed quadrants of a zero maze for males and females [n] Anxiety
X1382 11949 Anxiety assay, entries into open quadrants of a zero maze for males and females [n] Anxiety
X2143 11950 Anxiety assay, latency to enter an open quadrant of a zero maze for males and females [sec] Anxiety
X3759 11951 Anxiety assay, percentage time in open quadrants of a zero maze for males and females [%] Anxiety
X2723 11952 Anxiety assay, time in closed quadrants of a zero maze for males and females [sec] Anxiety
X2724 11953 Anxiety assay, time in open quadrants of a zero maze for males and females [sec] Anxiety
X1444 11968 Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males and females [n] Anxiety
X3159 11969 Anxiety assay, untreated baseline, entries into open arms of a plus maze for males and females [n] Anxiety
X3204 11970 Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males and females [%] Anxiety
X3276 11971 Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males and females [%] Anxiety
X1947 11972 Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males and females [%] Anxiety
X1657 11973 Anxiety assay, untreated baseline, percentage of time in open arms of plus maze for males and females [%] Anxiety
X1946 11980 Anxiety assay, time in closed arms of an elevated plus maze for males and females [sec] Anxiety
X1721 11981 Anxiety assay, time in middle of an elevated plus maze for males and females [sec] Anxiety
X1292 11982 Anxiety assay, time in open arms of an elevated plus maze for males and females [sec] Anxiety
X2090 12014 Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] Anxiety
X2447 12015 Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] Anxiety
X2000 12016 Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males and females [n beam breaks] Anxiety
X1508 12020 Novel open field behavior, locomotion in the center from 0-15 min for males and females [n beam breaks] Anxiety
X3265 12543 Transferrin saturation of 120-day-old males fed 3 ppm iron diet [%] Hematology
X3021 12021 Novel open field behavior, locomotion in the center from 15-30 min for males and females [n beam breaks] Anxiety
X1849 12022 Novel open field behavior, locomotion in the center from 30-45 min for males and females [n beam breaks] Anxiety
X2181 12023 Novel open field behavior, locomotion in the center from 45-60 min for males and females [n beam breaks] Anxiety
X1785 12024 Novel open field behavior, locomotion in the center from 0-15 min for males and females [cm] Anxiety
X2811 12025 Novel open field behavior, locomotion in the center from 15-30 min for males and females [cm] Anxiety
X2666 12026 Novel open field behavior, locomotion in the center from 30-45 min for males and females [cm] Anxiety
X2110 12027 Novel open field behavior, locomotion in the center from 45-60 min for males and females [cm] Anxiety
X2132 12028 Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males and females [n beam breaks] Anxiety
X1607 12029 Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males and females [n beam breaks] Anxiety
X2206 12030 Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males and females [n beam breaks] Anxiety
X2488 12031 Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males and females [n beam breaks] Anxiety
X2822 12032 Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X2553 12033 Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X2635 12034 Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X3452 12035 Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X2933 12036 Novel open field behavior, locomotion from 0-15 min in the periphery for males and females in the cocaine test battery [cm] Anxiety
X2363 12037 Novel open field behavior, locomotion from 15-30 min in the periphery for males and females in the cocaine test battery [cm] Anxiety
X3247 12038 Novel open field behavior, locomotion from 30-45 min in the periphery for males and females in the cocaine test battery [cm] Anxiety
X3644 12039 Novel open field behavior, locomotion from 45-60 min in the periphery for males and females in the cocaine test battery [cm] Anxiety
X1133 12040 Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males and females [n beam breaks] Anxiety
X762 12041 Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males and females [n beam breaks] Anxiety
X548 12042 Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males and females [n beam breaks] Anxiety
X518 12043 Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males and females [n beam breaks] Anxiety
X926 12044 Novel open field behavior, percentage of locomotion in the periphery for males and females [%] Anxiety
X3318 12045 Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [n beam breaks] Anxiety
X3236 12046 Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [cm] Anxiety
X397 12047 Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males and females [n beam breaks] Anxiety
X2146 12067 Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X2208 12068 Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [cm] Anxiety
X439 12069 Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] Anxiety
X4445 12335 Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] Anxiety
X3472 12336 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] Anxiety
X4789 12337 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] Anxiety
X4176 12338 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] Anxiety
X669 12339 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] Anxiety
X592 12340 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] Anxiety
X391 12341 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] Anxiety
X1490 12342 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] Anxiety
X3543 12343 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] Anxiety
X2609 12344 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] Anxiety
X1132 12345 Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] Anxiety
X4087 12762 Anxiety (center-distance ratio) in open-field (OFA) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% of WT] Anxiety
X4207 12346 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] Anxiety
X4299 12347 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] Anxiety
X3672 12348 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] Anxiety
X1212 12349 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] Anxiety
X1956 12350 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] Anxiety
X651 12351 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] Anxiety
X3226 12352 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] Anxiety
X3891 12353 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] Anxiety
X3099 12354 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] Anxiety
X656 12355 Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] Anxiety
X3953 12356 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] Anxiety
X4191 12357 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] Anxiety
X4381 12358 Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] Anxiety
X632 12359 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] Anxiety
X1831 12360 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] Anxiety
X545 12361 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] Anxiety
X1441 12362 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] Anxiety
X3478 12363 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] Anxiety
X1965 12364 Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] Anxiety
X2440 12365 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] Anxiety
X2847 12366 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during first 5 min [% time] Anxiety
X2365 12367 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percent time] Anxiety
X3961 12368 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during whole 10 min test [% time] Anxiety
X1119 12369 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] Anxiety
X348 12370 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] Anxiety
X454 12371 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] Anxiety
X5024 12372 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] Anxiety
X725 12373 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] Anxiety
X3178 12374 Anxiety assay, ethanol treated (1.8 g/kg ip) (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] Anxiety
X3208 12375 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] Anxiety
X4889 12376 Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] Anxiety
X4352 12377 Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] Anxiety
X4687 12378 Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] Anxiety
X3001 12379 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] Anxiety
X1270 12380 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] Anxiety
X1592 12381 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] Anxiety
X5091 12382 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] Anxiety
X5077 12383 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] Anxiety
X5092 12384 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] Anxiety
X4030 12385 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] Anxiety
X2535 12386 Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] Anxiety
X4420 12387 Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] Anxiety
X4454 12388 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] Anxiety
X2258 12389 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] Anxiety
X784 12390 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] Anxiety
X925 12391 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] Anxiety
X5064 12392 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] Anxiety
X4738 12394 Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (BXD102 winterized from 21.008 +-19.93 to 3.0 and BX Anxiety
X2418 12395 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] Anxiety
X2380 12396 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] Anxiety
X4121 13442 OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only Anxiety
X2259 12397 Anxiety assay, saline treated (0.18 ml/kg ip, NOS group), time in open quadrants only during last 5 min of test using an elevated zero maze for 60- to 120-day-old females [%] Anxiety
X3490 12398 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] Anxiety
X3375 12399 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] Anxiety
X686 12400 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] Anxiety
X889 12401 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] Anxiety
X3822 12402 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] Anxiety
X3137 12403 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] Anxiety
X4520 12404 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] Anxiety
X5006 12405 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] Anxiety
X3693 12406 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] Anxiety
X3228 12407 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] Anxiety
X2416 12408 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] Anxiety
X209 12409 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] Anxiety
X1796 12410 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] Anxiety
X462 12411 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] Anxiety
X3197 12412 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] Anxiety
X4787 17546 number of jumps observed from 0 to 20 min for females at 11 weeks of age [n] Anxiety
X3355 12413 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] Anxiety
X2688 12414 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] Anxiety
X5029 12415 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] Anxiety
X4849 12416 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] Anxiety
X4256 12417 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] Anxiety
X3903 12418 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] Anxiety
X457 12419 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] Anxiety
X332 12420 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] Anxiety
X228 12421 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] Anxiety
X2490 12422 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] Anxiety
X2645 12423 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] Anxiety
X2689 12424 Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] Anxiety
X5000 12425 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] Anxiety
X1243 12426 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [% time] Anxiety
X3898 12427 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [% time] Anxiety
X2702 12428 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] Anxiety
X4276 15962 Tuberculosis, bacterial load in lung [CFU] Immune
X3153 12429 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] Anxiety
X234 12430 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] Anxiety
X591 12431 Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] Anxiety
X5081 12432 Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip)(RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks/sec] Anxiety
X4809 12433 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] Anxiety
X4765 12434 Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg ip] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females over 10 min [beam breaks/sec] Anxiety
X4918 12435 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] Anxiety
X2557 12436 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] Anxiety
X3059 12437 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] Anxiety
X2680 12438 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] Anxiety
X3056 12439 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] Anxiety
X691 12440 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] Anxiety
X959 12441 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] Anxiety
X1485 12442 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks/sec] Anxiety
X4658 12443 Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg i.p.] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min (data for BXD77 (4.463 +/- Anxiety
X1928 17547 number of fecal boli observed from 0 to 20 min for females at 11 weeks of age [n] Anxiety
X5083 12444 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] Anxiety
X4800 12445 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] Anxiety
X2373 12446 Anxiety assay, restraint stress [15 min] and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [% time] Anxiety
X4287 12447 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] Anxiety
X4466 12448 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [% time] Anxiety
X1462 12449 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] Anxiety
X162 12450 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] Anxiety
X329 12451 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] Anxiety
X5080 12452 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] Anxiety
X4021 12453 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] Anxiety
X3712 12454 Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (data for BXD11 (16.419 +/-15. Anxiety
X5075 12455 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] Anxiety
X2673 12456 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] Anxiety
X4706 12457 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] Anxiety
X4612 12458 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] Anxiety
X2636 12546 Transferrin saturation of 120-day-old females fed 270 ppm iron diet [%] Hematology
X1871 12459 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] Anxiety
X507 12460 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] Anxiety
X638 12461 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] Anxiety
X3385 12462 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] Anxiety
X3017 12463 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] Anxiety
X3417 12464 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] Anxiety
X4464 12465 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] Anxiety
X4068 12466 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] Anxiety
X3306 12467 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] Anxiety
X3214 12468 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] Anxiety
X1666 12469 Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) for RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] Anxiety
X2983 12470 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] Anxiety
X1654 12471 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] Anxiety
X3299 12472 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] Anxiety
X3667 12473 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] Anxiety
X4544 12474 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] Anxiety
X5061 12475 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] Anxiety
X4169 12476 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] Anxiety
X3737 12477 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] Anxiety
X3941 12478 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] Anxiety
X539 12479 Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) in the RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam break Anxiety
X496 12480 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] Anxiety
X281 12481 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] Anxiety
X3541 12482 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] Anxiety
X4129 12483 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] Anxiety
X2999 12484 Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] Anxiety
X1326 12631 Anxiety assay (E5_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session Anxiety
X306 12632 Anxiety assay (E5_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [%] Anxiety
X1327 12633 Anxiety assay (E5_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. Anxiety
X307 12634 Anxiety assay (E5_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [sec] Anxiety
X3716 12635 Anxiety assay (E5_NR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of rears in the light side using a light-dark box in 8-12 week-old males during 5 min session [n beam breaks]. Anxiety
X381 12636 Anxiety assay (E10_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [%] Anxiety
X380 12637 Anxiety assay (E10_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec] Anxiety
X1580 12638 Anxiety assay (E10_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] Anxiety
X1581 12639 Anxiety assay (E10_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min sess Anxiety
X1719 12640 Anxiety assay (S5_PTR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min sessi Anxiety
X888 12641 Anxiety assay (S5_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [n %]. Anxiety
X1720 12642 Anxiety assay (S5_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. Anxiety
X887 12643 Anxiety assay (S5_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [n sec]. Anxiety
X3027 12644 Anxiety assay (S10_PTR), percent time spent without locomotion in the light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during 1 Anxiety
X1768 12645 Anxiety assay (S10_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [n %]. Anxiety
X3028 12646 Anxiety assay (S10_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] Anxiety
X1766 12647 Anxiety assay (S10_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec]. Anxiety
X2053 12760 Anxiety measured as center-distance:total distance ratio in the open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [ratio] Anxiety
X1908 12761 Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 mutant cases only [ratio] Anxiety
X2805 12544 Iron binding capacity in plasma of 120-day-old males fed 3 ppm iron diet [ug/dL] Hematology
X2828 13443 anxiety assay, number of fecal boli produced in an open field activity (OFA) test in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only Anxiety
X4485 13444 OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [% WT only] Anxiety
X4460 13460 Rearing in open field test by 8-week-old F1 hybrids generated by crossing male BXDs with female C57BL/6J-R6/2 Huntington carriers [n beam breaks] Anxiety
X4911 13533 OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTEd R6/2 cases only Anxiety
X4340 13536 Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 mutant cases only [ratio] Anxiety
X1765 17528 locomotion, total distance traveled from 0 to 20 min for males at 11 weeks of age [cm] Anxiety
X2964 17529 thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for males at 11 weeks of age [percent] Anxiety
X2534 17530 thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for males at 11 weeks of age [percent] Anxiety
X2864 17531 number of leans observed from 0 to 20 min for males at 11 weeks of age [n] Anxiety
X2906 17532 number of rears observed from 0 to 20 min for males at 11 weeks of age [n] Anxiety
X3642 17533 grooming frequency from 0 to 20 min for males at 11 weeks of age [n] Anxiety
X1421 17534 grooming duration observed from 0 to 20 min for males at 11 weeks of age [sec] Anxiety
X4097 17535 grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for males at 11 weeks of age [sec] Anxiety
X4354 17536 number of jumps observed from 0 to 20 min for males at 11 weeks of age [n] Anxiety
X2355 17537 number of fecal boli observed from 0 to 20 min for males at 11 weeks of age [n] Anxiety
X2642 17538 locomotion, total distance traveled from 0 to 20 min for females at 11 weeks of age [cm] Anxiety
X2482 17539 thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for females at 11 weeks of age [percent] Anxiety
X1514 17540 thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for females at 11 weeks of age [percent] Anxiety
X3052 17541 number of leans observed from 0 to 20 min for females at 11 weeks of age [n] Anxiety
X4409 17542 number of rears observed from 0 to 20 min for females at 11 weeks of age [n] Anxiety
X2310 17543 grooming frequency from 0 to 20 min for females at 11 weeks of age [n] Anxiety
X4103 17544 grooming duration observed from 0 to 20 min for females at 11 weeks of age [sec] Anxiety
X4700 17545 grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for females at 11 weeks of age [sec] Anxiety
X964 12932 Hemoglobin of 14-week old males [g/dl] Hematology
X2638 10008 Phencyclidine response (7.5 mg/kg ip), locomotor response, difference in activity (PCP minus saline) between 1 hr test periods [cm] Drug response
X2940 10009 Phencyclidine response (7.5 mg/kg ip), locomotor activity from 0-60 min after PCP injection [cm] Drug response
X1192 10011 Amphetamine response (5 mg/kg ip), locomotor response, difference in activity (amphetamine minus saline) between 1 hr test periods [cm] Drug response
X1289 10012 Amphetamine response (5 mg/kg ip), locomotor activity from 0-60 min after injection [cm] Drug response
X955 10016 Morphine response (variable doses, ip), induced hypothermia [slope of drug-response curve] Drug response
X4936 10017 Morphine response (variable doses ip), analgesia, slope of the drug response curve [slope] Drug response
X1075 10018 Morphine response (variable doses ip), Straub tail test response, slope of the dose response curve [slope] Drug response
X835 10021 Saline control response (vehicle ip), open field activity after injection (unpublished data from Belknap and Crabbe, 1992) [units] Drug response
X3874 10025 Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC) area under the curve [units] Drug response
X3380 10026 Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), corrected peak level [units] Drug response
X2993 10027 Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), difference between treated and baseline untreated [units] Drug response
X2577 10028 Ethanol response, withdrawal severity measured as the difference in handling-induced convulsion (HIC) scores from a saline control group (unpublished supplementary data) [units] Drug response
X3523 10029 Morphine response (16 mg/kg), analgesia relative to maximum possible effect [%] Drug response
X2450 10040 Ethanol response, blood ethanol concentration (BEC) at recovery of righting reflex (retro-orbital sinus sample) [mg/ml] Drug response
X4522 10041 Ethanol response (2.5 g/kg ip), duration of loss of righting reflex [minutes] Drug response
X713 10042 Ethanol response (2.5 g/kg ip), ataxia, screen test sensitivity measured as the latency to fall, saline response minus ethanol response [seconds] Drug response
X4085 10046 Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia 60 min after injection on day 1 measured as change from baseline temperature [degrees C] Drug response
X1183 10047 Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 2 compared to day 1 [degrees C] Drug response
X857 10048 Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 3 compared to day 1 [degrees C] Drug response
X3101 10050 Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), locomotion change relative to baseline [cm] Drug response
X2287 10051 Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), locomotion change relative to baseline [cm] Drug response
X3932 10052 Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] Drug response
X2257 10053 Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] Drug response
X3313 10055 Ethanol withdrawal handling induced convulsions (HIC), 2-12 hours after 4 g/kg 20% v/v ethanol injection (ip), area under curve [HIC AUC] Drug response
X3738 10063 Ethanol response, withdrawal-associated handling-induced convulsions (HIC) after a 72 hr exposure to ethanol vapor (with Pyrazole injections to inhibit EtOH metabolism) (0=no effect, 1=facial grimace during Drug response
X1855 10064 Ethanol response, area under the 25-hr curve for withdrawal following 72 hr exposure to air. Pyrazole injections were given daily to inhibit EtOH metabolism. Handling-induced convulsions (HIC) were scored ho Drug response
X1763 10065 Ethanol response (1.5 g/kg ip loading dose and 68.1 mg/kg pyrazole), chronic withdrawal, handling-induced convulsion score (HIC) corrected for response to pyrazole alone (difference between strain mean value Drug response
X4960 10066 Ethanol response (1.5 g/kg), blood ethanol concentration (BEC) normalization data set (BEC was stabilized to ~1.5 mg EtOH/ml blood using daily pyrazole injections) [mg/ml] Drug response
X3608 10067 Ethanol response (2 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] Drug response
X3615 10068 Ethanol response (3 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] Drug response
X4623 10069 Ethanol response (4 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] Drug response
X2661 10070 Ethanol response (2 g/kg ip), hypothermia after injection [degrees C] Drug response
X3040 10071 Ethanol response (3 g/kg ip), hypothermia after injection [degrees C] Drug response
X3535 10072 Ethanol response (4 g/kg ip), hypothermia after injection [degrees C] Drug response
X4833 10073 Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake relative to previous water Drug response
X2839 10074 Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake in 20-24 week-old males [g Drug response
X1922 10075 Saline response (saline injection ip), open field activity in 20-24 week-old males (control for ethanol trait 10077) [beam crossings] Drug response
X1452 10076 Ethanol response (2.5 g/kg ip), distance run in the grid test, 10-12 min after injection in 20-24 week-old males [n beam crossings] Drug response
X4728 10077 Ethanol response (1.33 g/kg ip), open field activity in 20-24 week-old males tested under dim light, 10-13 min after injection of saline (day 1) and ethanol (day 2), difference in number of beam crossings re Drug response
X3596 10082 Ethanol response (4 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] Drug response
X5044 10083 Ethanol response (3 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] Drug response
X3301 10084 Ethanol response (2 g/kg), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] Drug response
X2154 10085 Ethanol response (4 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] Drug response
X4908 10086 Ethanol response (3 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] Drug response
X2850 10087 Ethanol response (2 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] Drug response
X4721 10088 Ethanol response (2 g/kg ip), acute difference in locomotion between experimental ethanol-condidtioned and saline control group of males [activity counts/min] Drug response
X2276 10089 Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between activity after fourth ethanol trial and first trial [cm] Drug response
X2922 10090 Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in males in the experimental group over a 30 min trial test [% time] Drug response
X5039 10091 Saline control response (vehicle ip) of ethanol-treated (2 mg/kg ip) males, locomotion 1-5 min after saline injection, trial 4 (experimental group, prior ethanol exposure) [activity counts per min] Drug response
X2708 10092 Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 1 in males [activity counts per min] Drug response
X3622 10094 Locomotion from 1-5 min after a single saline i.p. injection for the control group of males [activity/min] Drug response
X4684 10095 Saline control response (vehicle, ip), locomotion of control group from 1-5 min after injection on trial 1 [activity/min] Drug response
X4868 10096 Locomotion from 1-5 min after a saline injection for the control group of males on trial 4 [activity/min] Drug response
X4052 10097 Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in experimental group males [s/min] Drug response
X5088 10098 Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired hole floor in experimental group males [s/min] Drug response
X3238 10100 Locomotion from 1-5 min after a single saline ip injection of saline vehicle for the experimental group on trial 1 [activity counts per min] Drug response
X2595 10102 Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 4 in males [activity counts per min] Drug response
X2333 10104 Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between experimental group (two prior exposures to ethanol) and saline control group on fourth conditioning day [activi Drug response
X2497 10105 Saline control response (0.9% ip), activity habituation in males [4th saline injection trial activity minus first saline activity trial activity] Drug response
X4368 10809 Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of males and females [ug/dL] Hematology
X2561 10120 Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] Drug response
X2942 10121 Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] Drug response
X1306 10122 Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] Drug response
X1708 10123 Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 15 to 20 min after injection [cm] Drug response
X1479 10124 Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] Drug response
X4210 10125 Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] Drug response
X2550 10126 Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] Drug response
X2253 10127 Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] Drug response
X1234 10128 Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 15-20 min after injection [cm] Drug response
X2140 10129 Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] Drug response
X3480 10135 Ethanol acceptance (10% in tap water after 24 hr water deprivation), raw mean consumption of adult males (same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg body weight] Drug response
X589 10136 Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 days, same data as in Rodriguez et al., 1994 with outliers removed and two strains added) [g/kg] Drug response
X4676 10137 Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult males (53-67 days, residual values and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg Drug response
X3979 10138 Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 day, residuals and same data as in Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] Drug response
X3206 10139 Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] Drug response
X1092 10140 Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] Drug response
X4545 10141 Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, residuals and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/ Drug response
X4744 10142 Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, residuals over a two week test period and same data as Rodriguez et al, 1994 with outliers remov Drug response
X3719 10817 Iron level in plasma of males [ug/dL] Hematology
X2599 10144 Ethanol response (escalating dose given ip), initial sensitivity measured as the ataxia onset threshold following first of five injections [mg/kg] Drug response
X4836 10145 Ethanol response (escalating dose given ip), maximal threshold to ethanol induced ataxia [mg/ml] Drug response
X3913 10146 Ethanol response (escalating dose given ip), tolerance, difference between ethanol induced ataxia (maximal threshold blood ethanol concentration BEC) minus onset threshold [mg/ml] Drug response
X3289 10147 Ethanol response (escalating dose given ip), tolerance measured as the fold-increase of blood ethanol concentration (BEC) to ethanol-induced ataxia [ratio of tolerance BEC over initial BEC ataxia] Drug response
X240 10169 Methamphetamine response (4 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] Drug response
X3278 10171 Methamphetamine response (16 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] Drug response
X3256 10172 Methamphetamine response (8 mg/kg ip), brain concentration in brain after injection in 10-14 week males [ug/gm] Drug response
X1250 10174 Methamphetamine response (4 mg/kg ip), brain concentration after injection in 10-14 week males [ug/gm] Drug response
X3135 10202 Cocaine response (variable dose, iv), dosage required to induce tonic seizure infused via tail vein [mg/kg] Drug response
X4645 10203 Cocaine response (variable dose iv via tail vein), dose required to induce clonic seizure [mg/kg] Drug response
X877 10286 Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males [n difference] Drug response
X3212 10287 Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in females [n difference] Drug response
X1105 10288 Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males and females [n difference] Drug response
X1389 10289 Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males [cm difference] Drug response
X2539 10290 Cocaine response (5 mg/kg ip), locomotion measured as difference from saline control in females [cm difference] Drug response
X2854 10291 Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males and females [cm difference] Drug response
X3867 10292 Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males [n] Drug response
X4690 10293 Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in females [n difference Drug response
X4668 10294 Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males and females [n difference] Drug response
X2040 10295 Cocaine response (15 mg/kg ip), cocaine stereotypy, number of movements as difference from saline control injection in males [n] Drug response
X2407 10316 Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] Drug response
X5084 10296 Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult females [n] Drug response
X3296 10297 Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult males and females [n] Drug response
X4736 10298 Cocaine response (15 mg/kg ip), locomotion in an open field, total distance measured as difference from saline control in males [cm] Drug response
X1348 10299 Cocaine response (15 mg/kg ip), open field activity, total distance, difference from saline control in females [cm] Drug response
X3686 10300 Cocaine response (15 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] Drug response
X4212 10301 Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] Drug response
X1101 10302 Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] Drug response
X4480 10303 Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] Drug response
X1279 10304 Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection for males [n] Drug response
X3753 10305 Cocaine response (30 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] Drug response
X2066 10306 Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection, male and female combined [n] Drug response
X1040 10307 Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] Drug response
X2863 10308 Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] Drug response
X2930 10309 Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] Drug response
X1202 10310 Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] Drug response
X4382 10311 Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] Drug response
X1034 10312 Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] Drug response
X2225 10313 Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males [n] Drug response
X3075 10314 Cocaine response (45 mg/kg ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] Drug response
X1026 10315 Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males and females [n] Drug response
X4673 12545 Plasma iron of 120-day-old males fed 3 ppm iron (Fe) diet [ug/dL] Hematology
X4093 10317 Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] Drug response
X2503 10318 Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] Drug response
X4963 10319 Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] Drug response
X1982 10320 Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] Drug response
X4621 10321 Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] Drug response
X2523 10322 Cocaine response (5 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] Drug response
X4017 10323 Cocaine response (15 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] Drug response
X3130 10324 Cocaine response (30 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] Drug response
X1745 10325 Cocaine response (45 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] Drug response
X5028 10326 Cocaine response (15 mg/kg ip), open field behavior, difference in time spent in the field center relative saline injection for females [sec] Drug response
X4112 10327 Cocaine response (30 mg/kg), open field behavior, center time (difference from saline) in males [sec] Drug response
X3532 10328 Cocaine response (30 mg/kg ip), open field behavior, center time difference from saline control in females [sec] Drug response
X3494 10329 Cocaine response (45 mg/k ip), open field center time relative to saline control in males [sec] Drug response
X2646 10330 Cocaine response (45 mg/k ip), open field center time relative to saline control in females [sec] Drug response
X528 10333 Cocaine response (5 mg/kg, ip), open field center time (difference from saline) in males [sec] Drug response
X5020 10334 Cocaine response (5 mg/kg), anxiety assay, center time in an open field test, difference from saline control in females [sec] Drug response
X4940 10335 Cocaine response (15 mg/kg ip), open field behavior, time in the field center (difference from saline control) in males [sec] Drug response
X3471 10347 Ethanol response (1.75 g/kg ip), initial sensitivity measured by blood ethanol concentration (BEC, retrobulbar bleed) at loss of balance using a dowel test (BEC time 0) [mg % ethanol] Drug response
X2604 10348 Ethanol response (1.75 g/kg ip then 2 g/kg ip), acute functional tolerance (AFT) measured as the difference in blood alcohol concentration (BEC, retrobulbar bleed) following the second recovery of balance an Drug response
X4838 10349 Ethanol response (1.75 mg/kg ip), time to ataxia measured as loss of balance using a dowel test (Loss corresponds to BEC time 0) [min] Drug response
X4927 10350 Ethanol response (1.75 mg/kg ip), duration of ataxia following the first ethanol injection using a dowel test (Regain Test 1 corresponds to BEC1) [min] Drug response
X4559 10351 Ethanol response (1.75 g/kg ip then 2 g/kg ip), duration of ataxia following the second ethanol injection using a dowel test (Regain Test 2 corresponds to BEC2) [min] Drug response
X1089 10352 cyclic AMP accumulation in cerebellum, basal level measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] Drug response
X2717 10353 cyclic AMP accumulation in cerebellum, stimuated with forskolin (10 uM) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] Drug response
X3809 10354 cyclic AMP accumulation in cerebellum, stimulated with isoproterenol (1 um) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] Drug response
X3395 10454 Allopregnanolone response (10 mg/kg 3a-hydroxy-5a-pregnan-20-one, THP, in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle Drug response
X3591 10455 Allopregnanolone response (17 mg/kg 3a-hydroxy-5a-pregnan-20-one in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle basel Drug response
X2008 10469 Morphine response (0.3 to 0.7 mg/ml in water), consumption using two-bottle choice test [ml/test period] Drug response
X3788 10474 Ethanol response (3%, g/kg in tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] Drug response
X2618 10475 Ethanol response (3%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] Drug response
X1678 10476 Ethanol response (10%, g/kg in tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] Drug response
X1976 10477 Ethanol response (10%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] Drug response
X4484 10478 Ethanol response, withdrawal severity, handling-induced convulsion (HIC) score, corrected area under the HIC curve after voluntary ethanol consumption [HIC AUC] Drug response
X2304 10479 Ethanol response (10%, g/kg in tap water), preference using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [ratio] Drug response
X4511 10480 Water response, consumption using a two-bottle choice test offered vs. 10% ethanol [ml] Drug response
X4824 10481 Water response, consumption using a two-bottle choice test offered vs. 0.2% saccharin [ml] Drug response
X697 10482 Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injections, difference between day 2 saline control and day 11 ethanol injection (first and only ethanol i Drug response
X2076 10483 Ethanol response (2 g/kg ip), sensitization to ethanol, difference in locomotor activity between saline control group (CS) and ethanol treated group (CD) to final acute ethanol test on day 11 (deltaBG) [cm] Drug response
X4914 10484 Ethanol response (2 g/kg ip), sensitization to ethanol (CD group), difference in locomotor activity between fifth ethanol treatment (day 11) and first ethanol treatment (day 3), 1- 5 min after injections in Drug response
X551 10485 Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injection, difference between day 2 saline injection response and day 3 ethanol injection in young adult f Drug response
X1792 10488 Cocaine response (10 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] Drug response
X1179 10489 Cocaine response (40 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] Drug response
X4844 10490 Cocaine response (10 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] Drug response
X1645 10491 Cocaine response (40 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] Drug response
X3565 10492 Cocaine response (5 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] Drug response
X2919 10493 Cocaine response (5 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] Drug response
X1304 10494 Ethanol response (2 g/kg ip), difference in locomotion using grid test (Accuscan activity monitor) following ethanol injection, day 3 (first treatment) minus day 2 (saline baseline) in the chronic ethanol gr Drug response
X2427 10495 Ethanol response (2 g/kg ip), difference in locomotion between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline group [n beam breaks/10 min test] Drug response
X4535 10496 Ethanol response (2 g/kg ip), sensitization to ethanol measured as the difference in locomotion using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (fir Drug response
X4477 10497 Ethanol response (2 g/kg ip), acute ataxia, difference between day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic drug group [n grid test errors/10 min test] Drug response
X2109 10498 Ethanol response (2 g/kg ip), acute ataxia measured using using grid test (Accuscan activity monitor), difference between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic Drug response
X4792 10499 Ethanol response (2 g/kg ip), intoxication and adaptation measured as difference in missteps using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (first Drug response
X3806 10500 Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between acute ethanol on day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic ethanol grou Drug response
X3354 10589 Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex [min] Drug response
X4657 10501 Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between injection on day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline Drug response
X1617 10502 Ethanol response, change in ataxic effects of 2 g/kg (ip) after repeated treatment, difference between day 11 (fifth treatment) minus day 3 (first treatment) in the chronic drug (CD) group, 10 min test [grid Drug response
X3442 10563 Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 16-20 min after injection [activity counts/min] Drug response
X3992 10564 Control response (10 mg/kg oil vehicle), locomotor activity 16-20 min after injection [activity counts/min] Drug response
X4773 10565 Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 21-25 min after injection [activity counts/min] Drug response
X2023 10566 Control response (10 mg/kg oil vehicle), locomotor activity 21-25 min after injection [activity counts/min] Drug response
X4631 10567 Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 26-30 min after injection [activity counts/min] Drug response
X2954 10568 Control response (10 mg/kg oil vehicle), locomotor activity 26-30 min after injection [activity counts/min] Drug response
X1036 10569 Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 0-15 min after injection [activity counts/min] Drug response
X3665 10570 Control response (10 mg/kg oil vehicle), locomotor activity from 0-15 min after injection [activity counts/min] Drug response
X4035 10571 Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 15-30 min after injection [activity counts/min] Drug response
X3911 10572 Control response (10 mg/kg oil vehicle), locomotor activity from 15-30 min after injection [activity counts/min] Drug response
X3929 10578 Ethanol response (4 g/kg ip), handling-induced convulsion (HIC) score 7 hr after injection [score] Drug response
X870 10581 Ethanol response (10% in water po), acceptance, total consumption over 24 hr for females [g/kg] Drug response
X3093 10582 Ethanol response (10% in water po), acceptance, total consumption over 24 hr for males [g/kg] Drug response
X933 10583 Ethanol response (10% in water po), preference for alcohol for females [g/kg] Drug response
X2055 10584 Ethanol response (10% v/v in water), preference of females using 2-bottle choice [g/kg] Drug response
X4912 10585 Ethanol response (variable dose ip), hypnotic dose sensitivity (HDS), sleep time for females [min] Drug response
X1258 10586 Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex of males [min] Drug response
X1386 10587 Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake [g/kg] Drug response
X1683 10588 Ethanol response (10% in water po), preference and consumption of 10% ethanol vs. water over 15 days [g/kg] Drug response
X1236 10609 Cocaine response (32 mg/kg ip), locomotion from 0-60 min after injections in an activity chamber [n beam breaks] Drug response
X4269 10610 Cocaine response (32 mg/kg ip), sensitization of locomotor response [% initial response] Drug response
X2603 10611 Cocaine response (32 mg/kg ip, daily), stereotypical behavior frequency after consecutive daily injections on day 8 [units] Drug response
X2921 10614 Pentylenetetrazol (PTZ, a GABA antagonists) response, dosage level (threshold) required to induce seizure [mg/kg] Drug response
X4128 10790 Ethanol response (1.5 g/kg ip), locomotion during 0 to 5 min interval (updated data PMID 9880575) [cm] Drug response
X1918 10791 Ethanol response (1.5 g/kg ip), locomotion during 5 to 10 min interval (updated data PMID 9880575) [cm] Drug response
X2174 10792 Ethanol response (1.5 g/kg ip), locomotion during 10 to 15 min interval (updated data PMID 9880575) [cm] Drug response
X1804 10793 Ethanol response (1.5 g/kg ip), locomotion during 15 to 20 min interval (updated data PMID 9880575) [cm] Drug response
X4402 10794 Ethanol response (1.5 g/kg ip), adaptation to ethanol defined as 15-20 min interval locomotion minus 0-5 min interval locomotion [cm] Drug response
X3287 11002 Ethanol response (3 g/kg ip), hypothermia (supplementary data to Brigman et al.) [deg C] Drug response
X832 11003 Ethanol response (3 g/kg ip), loss of righting reflex (LORR) sleep time (supplementary data to Brigman et al.) [min] Drug response
X724 11006 Ethanol response (1.75 g/kg ip), ataxia measured by rotarod performance, difference from saline baseline (supplementary data to Brigman et al.) Drug response
X3625 11303 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males [sec] Drug response
X3435 11304 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males [sec] Drug response
X296 11312 Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males [n beam breaks] Drug response
X611 11313 Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males [n beam breaks] Drug response
X2283 11314 Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males [n beam breaks] Drug response
X2948 11315 Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males [n beam breaks] Drug response
X4314 11316 Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males [n beam breaks] Drug response
X2148 11317 Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males [n beam breaks] Drug response
X1659 11318 Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males [n beam breaks] Drug response
X224 11319 Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males [n beam breaks] Drug response
X99 11320 Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males [n beam breaks] Drug response
X102 11321 Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males [n beam breaks] Drug response
X172 11322 Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males [n beam breaks] Drug response
X188 11323 Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males [cm] Drug response
X375 11324 Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males Drug response
X1476 11325 Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males [cm] Drug response
X1728 11326 Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males [cm] Drug response
X3640 11327 Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for males [cm] Drug response
X1526 11328 Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males [cm] Drug response
X446 11329 Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males [cm] Drug response
X117 11330 Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males [cm] Drug response
X83 11331 Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males [cm] Drug response
X87 11332 Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males [cm] Drug response
X116 11333 Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males [cm] Drug response
X4077 11334 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males [ordinal scale, 0=no effect, 3=max] Drug response
X3987 11335 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males [n fecal boli] Drug response
X985 11336 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males [n/15 min test] Drug response
X138 11337 Morphine response (50 mg/kg ip), locomotion from 0-180 min after injection (total open field activity over 3 hour test) for males [n beam breaks] Drug response
X114 11338 Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males [cm] Drug response
X1864 11339 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) [ Drug response
X841 11340 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min after injection (total vertical activity over 3 hour test) for males [n beam breaks] Drug response
X1915 11356 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males [n beam breaks] Drug response
X1613 11357 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males [cm] Drug response
X2068 11358 Morphine response (50 mg/kg ip) and naloxone response (30 mg/kg ip), naloxone-induced withdrawal after morphine, vertical activity (rears) from 0-15 min for males [n beam breaks] Drug response
X3605 11359 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males [ordinal scale, 0=no effect, 3=max] Drug response
X4367 11360 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males [ordinal scale, 0=no effect, 3=max] Drug response
X1576 11361 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males [ordinal scale, 0=control level, 3=max] Drug response
X4935 11362 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] Drug response
X904 11364 Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males [n beam breaks] Drug response
X2748 11365 Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males [n beam breaks] Drug response
X4111 11366 Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males [n beam breaks] Drug response
X3111 11367 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males [n beam breaks] Drug response
X2332 11368 Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males [n beam breaks] Drug response
X1900 11369 Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males [n beam breaks] Drug response
X314 11370 Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males [n beam breaks] Drug response
X139 11371 Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males [n beam breaks] Drug response
X165 11372 Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males [n beam breaks] Drug response
X341 11373 Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males [n beam breaks] Drug response
X4718 10820 Hematocrit (packed cell volume, erythrocyte volume fraction) in males and females [%] Hematology
X610 11374 Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males [n beam breaks] Drug response
X2771 11375 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males [cm/90 min test] Drug response
X3386 11378 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males [explain the score] Drug response
X3752 11379 Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion Drug response
X1502 11380 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males [units] Drug response
X1344 11382 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during s Drug response
X523 11440 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males [cm] Drug response
X1498 11441 Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males [cm] Drug response
X573 11442 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males [cm] Drug response
X1098 11444 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males [cm] Drug response
X1230 11446 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males [cm] Drug response
X1676 11447 Saline control response (10 ml/kg ip) for cocaine, locomotion from 15-20 min after injection for males [cm] Drug response
X2844 11448 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males [cm] Drug response
X1141 11449 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males [cm] Drug response
X2049 11450 Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males [cm] Drug response
X1218 11451 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males [cm] Drug response
X1504 11452 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males [cm] Drug response
X3225 11453 Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males [mg/dl XX min after injection] Drug response
X3834 11460 Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males and females [sec] Drug response
X2527 11461 Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males [sec] Drug response
X4874 11462 Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for males [sec] Drug response
X4204 12934 Potassium of 14-week old males [mM] Hematology
X155 11463 Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males [sec] Drug response
X3291 11469 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [n beam breaks] Drug response
X3975 11470 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [n beam breaks] Drug response
X4548 11471 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [n beam breaks] Drug response
X3468 11472 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [n beam breaks] Drug response
X3569 11473 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [cm] Drug response
X4095 11474 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [cm] Drug response
X4456 11475 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [cm] Drug response
X2895 11476 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [cm] Drug response
X1260 11477 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males [n beam breaks] Drug response
X980 11478 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males [n beam breaks] Drug response
X2394 11479 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males [n beam breaks] Drug response
X2114 11480 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males [n beam breaks] Drug response
X2457 11481 Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males [n beam breaks] Drug response
X2809 11482 Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males [n beam breaks] Drug response
X4486 11484 Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males [n beam breaks] Drug response
X3173 11485 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males [cm] Drug response
X3483 11486 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males [cm] Drug response
X3637 11487 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males [cm] Drug response
X4009 11488 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males [cm] Drug response
X1107 11489 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] Drug response
X1734 11490 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] Drug response
X1044 11491 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males [n beam breaks] Drug response
X2051 11492 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males [n beam breaks] Drug response
X3881 11495 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for males [sec], Drug response
X2377 11496 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for males [sec] Drug response
X3847 11498 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [sec] Drug response
X3765 11499 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage of time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [% cha Drug response
X3894 11503 Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males [n beam breaks] Drug response
X3947 11504 Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males [cm] Drug response
X1814 11505 Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for males [n beam breaks] Drug response
X1987 11534 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [n beam breaks] Drug response
X2134 11535 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [cm] Drug response
X2117 11536 Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males [n beam breaks/60 min] Drug response
X3747 11537 Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males [difference in cm/1 hr test, positive values indicate sensitizat Drug response
X3802 11538 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [n beam breaks, positive values indicate sensitization] Drug response
X4366 11539 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [cm, positive values indicate sensitization] Drug response
X996 11540 Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males between first and second injections [difference in n/1 hr test, positive values indicate sensitization] Drug response
X3087 11541 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [n beam breaks/15 min] Drug response
X4158 10822 Transferrin saturation of males [%] Hematology
X2299 11542 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [n beam breaks/15 min] Drug response
X3347 11543 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [n beam breaks/15 min] Drug response
X1954 11544 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [n beam breaks/15 min] Drug response
X2586 11545 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [cm] Drug response
X2388 11546 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [cm] Drug response
X3800 11547 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [cm] Drug response
X2551 11548 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [cm] Drug response
X1200 11549 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males [n beam breaks/15 min] Drug response
X2116 11550 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males [n beam breaks/15 min] Drug response
X2526 11551 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males [n beam breaks/15 min] Drug response
X3242 11552 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males [n beam breaks/15 min] Drug response
X4628 11560 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for females [sec] Drug response
X3948 11561 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for females [sec] Drug response
X631 11569 Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for females [n beam breaks] Drug response
X2504 11570 Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for females [n beam breaks] Drug response
X2411 11571 Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for females [n beam breaks] Drug response
X1286 11572 Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for females [n beam breaks] Drug response
X940 11573 Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for females [n beam breaks] Drug response
X257 11574 Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for females [n beam breaks] Drug response
X1054 11575 Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for females [n beam breaks] Drug response
X260 11576 Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for females [n beam breaks] Drug response
X161 11577 Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for females [n beam breaks] Drug response
X182 11578 Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for females [n beam breaks] Drug response
X291 11579 Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for females [n beam breaks] Drug response
X535 11580 Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for females [cm] Drug response
X2187 11581 Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for females [cm] Drug response
X1138 11582 Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for females [cm] Drug response
X1401 11583 Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for females [cm] Drug response
X627 11584 Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for females [cm] Drug response
X249 11585 Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for females [cm] Drug response
X480 11586 Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for females [cm] Drug response
X158 11587 Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for females [cm] Drug response
X115 11588 Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for females [cm] Drug response
X143 11589 Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for females [cm] Drug response
X244 11590 Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for females [cm] Drug response
X4951 11591 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for females [ordinal scale, 0=no effect, 3=max] Drug response
X4187 11592 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for females [n fecal boli] Drug response
X4655 11593 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for females [n/15 min test] Drug response
X289 11594 Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] Drug response
X246 11595 Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [cm] Drug response
X896 11630 Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for females [n beam breaks] Drug response
X438 11596 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for females (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) Drug response
X2082 11597 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] Drug response
X1739 11613 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for females [n beam breaks] Drug response
X1528 11614 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for females [cm] Drug response
X2782 11615 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for females [n beam breaks] Drug response
X4326 11616 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for females [ordinal scale, 0=no effect, 3=max] Drug response
X3576 11617 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for females [ordinal scale, 0=no effect, 3=max] Drug response
X3840 11618 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for females [ordinal scale, 0=control level, 3=max] Drug response
X2598 11619 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for females [ordinal scale, 0=no effect, 3=max] Drug response
X3221 11621 Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for females [n beam breaks] Drug response
X2995 11622 Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for females [n beam breaks] Drug response
X2448 11623 Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for females [n beam breaks] Drug response
X1358 11624 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for females [n beam breaks] Drug response
X1916 11625 Morphine response (50 mg/kg ip), vertical activity (rears) 150-165 min after injection in an activity chamber for females [n beam breaks] Drug response
X1497 11626 Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for females [n beam breaks] Drug response
X1491 11627 Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for females [n beam breaks] Drug response
X396 11628 Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for females [n beam breaks] Drug response
X476 11629 Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for females [n beam breaks] Drug response
X2194 11631 Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for females [n beam breaks] Drug response
X4429 11635 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion Drug response
X4491 11636 Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsio Drug response
X2773 11637 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for females [units] Drug response
X3945 11639 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during Drug response
X1374 11697 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for females [cm] Drug response
X368 11699 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for females [cm] Drug response
X1102 11701 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for females [cm] Drug response
X327 11703 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for females [cm] Drug response
X1407 11705 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for females [cm] Drug response
X1655 11706 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for females [cm] Drug response
X1813 11708 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for females [cm] Drug response
X285 11709 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for females [cm] Drug response
X2032 11717 Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for females [sec] Drug response
X1955 11718 Ethanol response (2.25 g/kg ip), duration on rotarod following injection for females [sec] Drug response
X2088 11719 Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for females [sec] Drug response
X3196 11720 Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for females [sec] Drug response
X780 11726 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [n beam breaks] Drug response
X729 11727 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [n beam breaks] Drug response
X2499 11728 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [n beam breaks] Drug response
X2378 11729 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [n beam breaks] Drug response
X506 11730 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [cm] Drug response
X986 11731 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [cm] Drug response
X2936 11732 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [cm] Drug response
X2316 11733 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [cm] Drug response
X324 11734 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for females [n beam breaks] Drug response
X605 11735 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for females [n beam breaks] Drug response
X613 11736 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for females [n beam breaks] Drug response
X643 11737 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for females [n beam breaks] Drug response
X609 11738 Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for females [n beam breaks] Drug response
X1064 11739 Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for females [n beam breaks] Drug response
X1704 11740 Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for females [n beam breaks] Drug response
X3180 11741 Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for females [n beam breaks] Drug response
X403 11742 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for females [cm] Drug response
X1165 11743 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for females [cm] Drug response
X1925 11744 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for females [cm] Drug response
X3211 11745 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for females [cm] Drug response
X1007 11746 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] Drug response
X1223 11747 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] Drug response
X542 11748 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for females [n beam breaks] Drug response
X2191 11749 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for females [n beam breaks] Drug response
X4399 11750 Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for females [sec] Drug response
X483 11751 Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for females [sec] Drug response
X4614 11752 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for females [sec] Drug response
X3826 11753 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for females [sec] Drug response
X4490 11755 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [sec] Drug response
X3126 11756 Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [% chan Drug response
X1142 11760 Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for females [n beam breaks] Drug response
X942 11761 Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for females [cm] Drug response
X361 11762 Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for females [n beam breaks] Drug response
X1251 11791 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [n beam breaks] Drug response
X1436 11792 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [cm] Drug response
X259 11793 Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for females [n beam breaks/60 min] Drug response
X4729 11794 Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for females [difference in cm/1 hr test, positive values indicate sensitiz Drug response
X1117 11795 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [n beam breaks, positive values indicate sensitization] Drug response
X1178 11796 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [cm, positive values indicate sensitization] Drug response
X785 11797 Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for females between first and second injections [difference in n/1 hr test, positive values indicate sensitization] Drug response
X1596 11798 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [n beam breaks/15 min] Drug response
X571 11799 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [n beam breaks/15 min] Drug response
X1261 11800 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [n beam breaks/15 min] Drug response
X1437 11801 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [n beam breaks/15 min] Drug response
X1085 11802 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [cm] Drug response
X645 11803 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [cm] Drug response
X1323 11804 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [cm] Drug response
X1775 11805 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [cm] Drug response
X226 11806 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for females [n beam breaks/15 min] Drug response
X435 11807 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for females [n beam breaks/15 min] Drug response
X386 11808 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for females [n beam breaks/15 min] Drug response
X400 11809 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for females [n beam breaks/15 min] Drug response
X2759 11817 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males and females [sec] Drug response
X1163 11818 Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males and females [sec] Drug response
X795 11821 Pain response, thermal nociception, Hargreaves' test for males and females Drug response
X2145 11822 Pain response, thermal nociception, hot plate test, average of two trials for males and females [sec] Drug response
X833 11823 Pain response, mechanical nociception, tail clip latency for males and females [sec] Drug response
X1412 11824 Pain response, thermal nociception, tail withdrawal latency for males and females [sec] Drug response
X189 11826 Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X447 11827 Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X2099 11828 Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X1511 11829 Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X505 11830 Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X243 11831 Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X845 11832 Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X169 11833 Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X101 11834 Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X100 11835 Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X134 11836 Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X163 11837 Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males and females [cm] Drug response
X342 11838 Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males and females [cm] Drug response
X1366 11839 Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males and females [cm] Drug response
X1522 11840 Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males and females [cm] Drug response
X410 11841 Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injections in an activity chamber for males and females [cm] Drug response
X231 11842 Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males and females [cm] Drug response
X267 11843 Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males and females [cm] Drug response
X108 11844 Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males and females [cm] Drug response
X84 11845 Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males and females [cm] Drug response
X91 11846 Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males and females [cm] Drug response
X112 11847 Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males and females [cm] Drug response
X3998 11848 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males and females [ordinal scale, 0=no effect, 3=max] Drug response
X2412 10749 HDL cholesterol level following 16-week high-fat diet [mg/dL] Hematology
X3804 11849 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males and females [n fecal boli] Drug response
X3666 11850 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males and females [n/15 min test] Drug response
X132 11851 Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] Drug response
X118 11852 Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [cm] Drug response
X333 11853 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males and females (last 15 min of morphine test (165-180 min) minus first 15 min after Drug response
X987 11854 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] Drug response
X1184 11870 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males and females [n beam breaks] Drug response
X916 11871 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males and females [cm] Drug response
X3833 11872 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for males and females [n beam breaks] Drug response
X3198 11873 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males and females [ordinal scale, 0=no effect, 3=max] Drug response
X2492 11874 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males and females [ordinal scale, 0=no effect, 3=max] Drug response
X3983 11875 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males and females [ordinal scale, 0=control level, 3=max] Drug response
X2937 11876 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] Drug response
X1203 11878 Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X2004 11879 Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X2718 11880 Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X1394 11881 Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X1577 11882 Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X650 11883 Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X825 11884 Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X142 11885 Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X171 11886 Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X382 11887 Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X801 11888 Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males and females [n beam breaks] Drug response
X2371 11889 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males and females [cm/90 min test] Drug response
X4034 11892 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males and females [ordinal scale] Drug response
X2348 11894 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males and females [ordinal scale] Drug response
X3368 11896 Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males and females [ordinal scale] Drug response
X4221 11954 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] Drug response
X2931 11955 Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] Drug response
X4184 11956 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males and females [cm] Drug response
X1143 11957 Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males and females [cm] Drug response
X1492 11958 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] Drug response
X683 11959 Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] Drug response
X796 11960 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males and females [cm] Drug response
X602 11961 Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for males and females [cm] Drug response
X4154 11962 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males and females [cm] Drug response
X2150 10750 HDL cholesterol levels following 16-week chow diet (control group) [mg/dL] Hematology
X3369 11963 Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males and females [cm] Drug response
X851 11964 Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males and females [cm] Drug response
X4961 11965 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males and females [cm] Drug response
X1692 11966 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males and females [cm] Drug response
X1859 11967 Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males and females [mg/dl XX min after injection] Drug response
X2169 11974 Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males females [sec] Drug response
X1030 11975 Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males and females [sec] Drug response
X4910 11976 Ethanol response (2.25 g/kg ip), time on rotarod after saline minus time on rotarod after ethanol for males and females [sec] Drug response
X1373 11977 Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males and females [sec] Drug response
X2781 11978 Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for males and females [sec] Drug response
X2152 11983 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [n beam breaks] Drug response
X2136 11984 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [n beam breaks] Drug response
X2741 11985 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [n beam breaks] Drug response
X2529 11986 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [n beam breaks] Drug response
X1537 11987 Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [cm] Drug response
X2009 11988 Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [cm] Drug response
X3097 11989 Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [cm] Drug response
X2399 11990 Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [cm] Drug response
X429 11991 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males and females [n beam breaks] Drug response
X719 11992 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males and females [n beam breaks] Drug response
X2213 10823 Transferrin saturation of males and females [%] Hematology
X912 11993 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males and females [n beam breaks] Drug response
X737 11994 Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males and females [n beam breaks] Drug response
X2368 11995 Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X1722 11996 Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X2081 11997 Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X3651 11998 Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X1658 11999 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males and females [cm] Drug response
X1628 12000 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males and females [cm] Drug response
X2345 12001 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males and females [cm] Drug response
X4172 12002 Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males and females [cm] Drug response
X715 12003 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X930 12004 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X504 12005 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X2033 12006 Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] Drug response
X4407 12007 Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males and females [sec] Drug response
X3083 12008 Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males and females [sec] Drug response
X4136 12009 Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on day 5 for males and females [sec] Drug response
X2620 12010 Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on day 5 for males and females [sec] Drug response
X4928 10825 Hemoglobin in males [g/dL] Hematology
X4297 12011 Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males and females [%] Drug response
X3997 12012 Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (day 5 minus day 1) for males Drug response
X4145 12013 Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (day 5 minus day 1 Drug response
X2327 12017 Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males and females [n beam breaks] Drug response
X2312 12018 Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males and females [cm] Drug response
X1255 12019 Cocaine response (10 mg/kg ip), vertical activity (rears) in the open field from 0-60 min after first cocaine injection for males and females [n beam breaks] Drug response
X1913 12048 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [n beam breaks] Drug response
X1582 12049 Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [cm] Drug response
X512 12050 Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males and females [n beam breaks/60 min] Drug response
X3914 12051 Cocaine response (2 x 10 mg/kg ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males and females [difference in cm/1 hr test, positive values indicate Drug response
X1951 12052 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [n beam breaks, positive values indicate sensitization] Drug response
X1998 12053 Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [cm, positive values indicate sensitization] Drug response
X642 12054 Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males and females between first and second injections [difference in n/1 hr test, positive values indicate sensitiza Drug response
X2239 12055 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [n beam breaks/15 min] Drug response
X1185 12056 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [n beam breaks/15 min] Drug response
X2067 12057 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [n beam breaks/15 min] Drug response
X2391 12058 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [n beam breaks/15 min] Drug response
X1843 12059 Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [cm] Drug response
X1282 12060 Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [cm] Drug response
X1878 12061 Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [cm] Drug response
X2375 12062 Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [cm] Drug response
X413 12063 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males and females [n beam breaks/15 min] Drug response
X680 12064 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males and females [n beam breaks/15 min] Drug response
X649 12065 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males and females [n beam breaks/15 min] Drug response
X793 12066 Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males and females [n beam breaks/15 min] Drug response
X5071 12393 Ethanol response (1.8 g/kg ip), anxiety assay in ethanol-treated (NOE) group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks/ Drug response
X4883 12565 Ethanol response (10% in tap water), average daily preference ratio, two-bottle choice in males and females [EtOH/water ratio] Drug response
X4263 12574 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 6th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X4117 12575 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 5th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X4697 12576 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 4th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X3012 12577 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 3rd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X2364 12578 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 2nd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X4059 12579 Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 1st week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] Drug response
X3920 12580 Ethanol response, consumption of 15% ethanol using a two-bottle choice systems (ethanol vs water), 2 h access, principal component 1 eigentrait (similar to residuals) based on weeks 1 through 6 data (Dec 200 Drug response
X2627 12586 Ethanol response (10% in tap water), average daily consumption, two-bottle choice, males and females [g/kg] Drug response
X4346 12623 Ethanol response (10% EtOH in tap water) average daily consumption, two bottle choice [g/kg], males Drug response
X2807 12624 Ethanol response (10% EtOH in tap water), average daily consumption using two-bottle choice method in females [g/kg] Drug response
X4043 12733 Ethanol response (10% v/v ethanol), average daily consumption at 2 hr, males and females combined [g/kg] Drug response
X2711 12741 Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 4th cycle of eth Drug response
X775 12742 Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 3rd cycle of eth Drug response
X2229 12743 Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 2nd cycle of eth Drug response
X4091 12744 Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 1st cycle of eth Drug response
X4703 12745 Ethanol response (chronic intermittent ethanol CIE cycles), baseline consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 before any ethano Drug response
X2903 12780 Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid (DOPAC) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old Drug response
X4898 12781 Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine (NE) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females ( Drug response
X4617 12782 Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 20 Drug response
X4174 12783 Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid (5-HIAA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old ma Drug response
X3606 12784 Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or femal Drug response
X3774 12785 Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old Drug response
X4510 12786 Control for ethanol response, norepinephrine (NE) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/ Drug response
X5050 12787 Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec Drug response
X3026 10826 Hemoglobin in males and females [g/dL] Hematology
X4948 12788 Control for ethanol response, 5-hydroxyindoleacetic acid (5-HIAA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 Drug response
X3207 12789 Control for ethanol response, homovanilic acid (HVA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ Drug response
X4527 12790 Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2 Drug response
X4534 12791 Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine levels (NE) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec Drug response
X2897 12792 Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid levels (DOPAC) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old mal Drug response
X3725 12793 Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Co Drug response
X2211 12794 Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid levels (5-HIAA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males Drug response
X1340 12795 Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 Drug response
X3713 12796 Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or f Drug response
X4292 12797 Control for ethanol response, norepinephrine (NE) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X2264 12798 Ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC, a dopamine metabolite) in the medial septal nucleus 72 h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 15 to 17 week Drug response
X2204 12799 Control for ethanol response, dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X4450 12800 Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in the medial septal nucleus 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or fem Drug response
X2727 12801 Control for ethanol response, homovanillic acid (HVA) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X2705 10751 LDL cholesterol levels following 16-week chow diet (control group) [mg/dL] Hematology
X3967 12802 Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho Drug response
X3399 12803 Ethanol response (chronic intermittent vapor exposure CIE), norepinephrine (NE) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X2845 12804 Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [n Drug response
X3324 12805 Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), dopamine level in hindbrain tissue 72h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X2382 12806 Ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or f Drug response
X1432 12807 Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), homovanillic (HVA) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg Drug response
X805 12808 Ethanol response, 5-hydroxytrptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort Drug response
X3990 12809 Control for ethanol response, norepinephrine (NE) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X4854 12810 Control for ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ Drug response
X1872 12811 Control for ethanol response, dopamine levels (DA) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X3294 12812 Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec Drug response
X2105 12813 Control for ethanol response, homovanillic acid (HVA, a dopamine metabolite) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho Drug response
X3230 12814 Control for ethanol response, 5-hydroxytryptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort 1) [ng/mg Drug response
X4114 12815 Control for ethanol response, dopamine (DA) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] Drug response
X4701 10752 Cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] Hematology
X4452 12940 Mean corpuscular hemoglobin of 14-week old males [pg] Hematology
X3161 12816 Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access, 3 days after 1st cycle of ethanol vapor chamber treatme Drug response
X229 12817 Ethanol response, ethanol consumption using a 2-bottle choice with 2 h access/day from day 3 to day 8 after the fourth cycle of treatment in a chronic intermittent ethanol vapor chamber (CIE) [g/kg/2h/day] Drug response
X1919 12961 Ethanol response, ethanol intake using a 2-bottle choice test, 2h access after cycle 4 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake [g/kg/2h] Drug response
X661 12963 Ethanol response, ethanol intake using a 2-bottle choice test, 2 h access after the second cycle of air exposure (control for CIE) in vapor chamber (average of 5 days ethanol intake, young adult males or females [g/kg Drug response
X1000 12964 Ethanol response, ethanol intake using a 2-bottle choice test, 2 hr access after cycle 1 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake, 16 to 18 weeks males or females [g/ Drug response
X4247 12965 Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after first cycle of exposure, intake over 5 days [g/kg/2h] Drug response
X1759 12967 Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after third cycle of exposure, intake over 5 days [g/kg/2h] Drug response
X3110 13018 Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day),handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old males Drug response
X1309 13565 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in normally housed group, control for chronic mild stress (CMS) group (Phas Drug response
X1959 13566 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in chronic mild (CMS) stress group 1 week before start of 7 weeks of CMS (Ph Drug response
X2774 13567 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, first DID), difference between chronic mild stress (CMS) and control groups one week before the s Drug response
X623 13568 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID phase) in females, control group for chronic mild stress (CMS) group (Phase 2) [g/kg] Drug response
X3062 13569 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, chronic mild stress (CMS) group (Phase 2) [g/kg] Drug response
X1015 13570 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, difference between chronic mild stress (CMS) group and control group (Pha Drug response
X5015 13571 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID)in females, in the control group for the chronic mild stress (CMS) group (Phase 3) [g/k Drug response
X2785 13572 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, chronic mild stress (CMS) group following CMS (Phase 3) [g/kg] Drug response
X4300 13573 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, difference between chronic mild stress (CMS) group and control group follo Drug response
X2509 13574 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the control group [g/kg] Drug response
X2494 13575 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the chronic mild stress (CMS) group [g Drug response
X701 13576 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) in the control group for chronic mild str Drug response
X4637 13577 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) for the chronic mild stress (CMS) group [ Drug response
X1048 13578 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the control group for chronic mild st Drug response
X3652 13579 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the chronic mild stress (CMS) group [ Drug response
X4536 14803 Nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, dark bars) [sec] Drug response
X2975 14804 Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, light bars) [sec] Drug response
X2868 14805 Nicotine response (0.5mg/kg, sc, twice a day on days 2-4), post-conditioning scores on day 5 in 7-8-week old males (supplementary data) [sec] Drug response
X4211 14806 Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, post-conditioning score on day 5 of CPP in 7-8-week old males (supplementary data) [score] Drug response
X418 15572 Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), number of somatic signs observed in 8- to 12-week-old males during 20 min session [n] Drug response
X4150 15573 withdrawal anxiety assay (Nic_Sal_Som), 7-day nicotine-treated (24mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), number of somatic signs observedin 8-12 week old males during 20 minute session [ Drug response
X1076 15574 Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2 mg/kg, s.c.), percent time spent in open arms of the elevated plus maze in 8-12 week old males during 5 Drug response
X4607 10753 LDL cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] Hematology
X1653 15575 Nicotine response (nicotine at 24 mg/kg/day for 7 days, s.c. by minipump followed by s.c. saline injection on day 8), withdrawal anxiety, percentage of time spent in open arms of an elevated plus maze in 8-1 Drug response
X662 16180 Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 1 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] Drug response
X707 16184 Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) maximum after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] Drug response
X4500 16197 Difference in nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4) and saline response (0.9%, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (lower panel, Fi Drug response
X625 16375 Ethanol response, blood ethanol concentration (BEC) during 4th cycle of ethanol exposure in vapor chamber (not associated with voluntary consumption) for male or female (Dec 2009 Cohort 1) [mg%] Drug response
X2907 17329 Saline control response (0.9%, s.c., b.i.d., on days 1) for nicotine experiment, basal movement on day 1 in CPP box in 7-8-week old males Drug response
X1934 17330 Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, locomotor activity on day 5 in CPP box in 7-8-week old males Drug response
X4882 17331 Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, change in movement (post - basal movement) on day 5 of CPP in 7-8-week old males Drug response
X4038 17332 Nicotine response (0.5 mg/kg, s.c., b.i.d., on day 1), locomotor activity prior to conditioning (pre-drug paired side) in CPP box in 7-8-week old males Drug response
X1823 17333 Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), locomotor activity on test day (day 5) in CPP boxes in 7-8-week old males Drug response
X3668 17334 Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), change in movement (pre - post-drug paired side) on day 5 of CPP in 7-8-week old males Drug response
X3744 17335 Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate latency (sec) Drug response
X3445 17336 Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate activity (sec) Drug response
X2917 17337 Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate latency (sec) Drug response
X3403 17338 Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate activity (sec) Drug response
X928 18103 Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] Drug response
X1235 18104 Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks (control for chronic mild stress (CMS) group) [g/k Drug response
X1500 18105 Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks (control for chronic mild stress (CMS) group) [g/k Drug response
X3986 18106 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over Drug response
X2752 18107 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during last 4 weeks and 7 weeks follow Drug response
X4151 18108 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during first 5 weeks and last 4 weeks Drug response
X464 18114 Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] Drug response
X2232 18115 Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks of chronic mild stress (CMS) [g/kg] Drug response
X2084 18116 Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks following 7 weeks of chronic mild stress (CMS) [g/ Drug response
X2403 18117 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over Drug response
X2528 18118 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption for normally housed mice 4 weeks after Drug response
X869 18119 Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over Drug response
X81 10429 Serum amyloid P component level (APCS protein, endogenous SAP maps to Chr 1 at 174,8 Mb) [ug/ml] Hematology
X4139 10440 Red blood cell osmotic fragility, following treatment with 0.425% NaCl [% lysis] Hematology
X3707 10511 Blood glucose levels before 4 g/kg ip ethanol injection in females [mg/dl] Hematology
X4915 10512 Blood glucose levels before 4 g/kg ip ethanol injection in males [mg/dl] Hematology
X1551 10513 Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in females [mg/dl] Hematology
X4457 10514 Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in males [mg/dl] Hematology
X4632 10515 Blood glucose levels before saline ip control injection in females [mg/dl] Hematology
X4667 10516 Blood glucose levels before saline ip control injection in males [mg/dl] Hematology
X3348 10517 Blood glucose levels 120 min after saline control injection in females [mg/dl] Hematology
X4761 10518 Blood glucose levels 120 min after saline control injection in males [mg/dl] Hematology
X4451 10827 Iron binding capacity (systemic, total iron-binding capacity, TIBC, transferrin level) of males [ug/dL] Hematology
X3202 10828 Iron level in plasma of females [g/dL] Hematology
X1910 10829 Iron level in plasma of males and females [ug/dL] Hematology
X3601 10830 Transferrin saturation of females [%] Hematology
X4357 10831 Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of females [ug/dL] Hematology
X1790 10832 Hemoglobin in females [g/dL] Hematology
X4776 10833 Hematocrit (packed cell volume, erythrocyte volume fraction) in males [%] Hematology
X3750 10834 Hematocrit (packed cell volume, erythrocyte volume fraction) in females [%] Hematology
X3105 12073 Metabolism, Albumin-to-creatinine ratio (ABR) baseline control in males at 10-12 weeks of age [ratio of ug/mg] Hematology
X2530 12491 Hemoglobin of 120-day-old females fed 3 ppm iron (Fe) diet [ug/dl] Hematology
X2092 12492 Hematocrit of 120-day-old females fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] Hematology
X4540 12499 Hemoglobin of 120-day-old males fed 3 ppm Fe diet [ug/dl] Hematology
X4186 12500 Hematocrit of 120-day-old males fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] Hematology
X1319 12507 Hemoglobin of 120-day-old females fed 270 ppm Fe diet [ug/dl] Hematology
X3620 12508 Hematocrit of 120-day-old females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] Hematology
X78 12515 Hemoglobin of 120-day-old males fed 270 ppm Fe diet [ug/dl] Hematology
X352 12516 Hematocrit of 120-day-old males fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] Hematology
X4166 12523 Transferrin saturation in plasma of 120-day-old males and females fed 3 ppm Fe diet [%] Hematology
X4175 12524 Iron binding capacity (total) in plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] Hematology
X1571 12525 Iron level of plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] Hematology
X1204 12526 Hemoglobin of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] Hematology
X2024 12527 Hematocrit of 120-day-old males and females fed 3 ppm iron (Fe) diet [% packed red blood cells] Hematology
X2579 12534 Transferrin saturation in plasma of 120-day-old males and females fed 270 ppm Fe diet [%] Hematology
X4939 12535 Iron binding capacity (total) in plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] Hematology
X4696 12536 Iron level of plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] Hematology
X97 12537 Hemoglobin of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] Hematology
X654 12538 Hematocrit of 120-day-old males and females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] Hematology
X2295 12540 Transferrin saturation of 120-day-old females fed 3 ppm iron diet [%] Hematology
X4547 12541 Iron binding capacity in plasma of 120-day-old females fed 3 ppm iron diet [ug/dL] Hematology
X4901 12547 Iron binding capacity in plasma of 120-day-old females fed 270 ppm iron diet [ug/dL] Hematology
X4585 12548 Plasma iron of 120-day-old females fed 270 ppm iron diet [ug/dL] Hematology
X2622 12549 Transferrin saturation of 120-day-old males fed 270 ppm iron diet [%] Hematology
X3853 12550 Iron binding capacity in plasma of 120-day-old males fed 270 ppm iron diet [ug/dL] Hematology
X5035 12551 Plasma iron of 120-day-old males fed 270 ppm iron diet [ug/dL] Hematology
X2324 12821 Alpha-amylase of 14-week old females [U/l] Hematology
X853 12822 Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old females [U/L] Hematology
X979 12823 Albumin of 14-week old females [g/l] Hematology
X154 12824 Alkaline phosphatase of 14-week old females, (ALPL gene product) [U/l] Hematology
X3357 12825 Aspartate transaminase of 14-week old females [U/l] Hematology
X3551 12844 Calcium of 14-week old females [mM] Hematology
X4922 12845 Chloride of 14-week old females [mM] Hematology
X1272 12846 Creatinine of 14-week old females [uM] Hematology
X489 12855 Glucose after 4 hour fast of 14-week old females [mMl] Hematology
X3994 12861 Hematocrit of 14-week old females [%] Hematology
X3919 12862 Hemoglobin of 14-week old females [g/dl] Hematology
X3123 12864 Potassium of 14-week old females [mM] Hematology
X3746 12870 Mean corpuscular hemoglobin of 14-week old females [pg] Hematology
X628 12871 Mean cell hemoglobin concentration of 14-week old females [g/dl] Hematology
X198 12872 Mean red blood cell volume (MCV of standard complete blood count) of 14-week old females [fL] Hematology
X1936 12873 Sodium of 14-week old females [mM] Hematology
X992 12874 Phosphorus of 14-week old females [mM] Hematology
X692 12875 Platelet count of 14-week old females [x10^3/ul] Hematology
X4462 12877 Red blood cell count of 14-week old females [x10^6/ul] Hematology
X1675 12881 Cholesterol (total) of 14-week old females [mM] Hematology
X4049 12882 Triglyceride of 14-week old females [mM] Hematology
X3426 12883 Blood proteins (total) of 14-week old females [g/l] Hematology
X1988 12884 Urea of 14-week old females [mM] Hematology
X199 12888 White blood cell count of 14-week old females [x10^3/ul] Hematology
X4995 12891 Alpha-amylase of 14-week old males [U/l] Hematology
X1147 12892 Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old males [U/L] Hematology
X1623 12893 Albumin of 14-week old males [g/l] Hematology
X122 12894 Alkaline phosphatase of 14-week old males (ALPL gene product) [U/l] Hematology
X3817 12895 Aspartate transaminase of 14-week old males [U/l] Hematology
X4695 12914 Calcium of 14-week old males [mM] Hematology
X4682 12915 Chloride of 14-week old males [mM] Hematology
X3865 12916 Creatinine of 14-week old males [uM] Hematology
X3598 12925 Glucose after 4 hour fast of 14-week old males [mMl] Hematology
X323 12931 Hematocrit of 14-week old males [%] Hematology
X248 12941 Mean cell hemoglobin concentration of 14-week old males [g/dl] Hematology
X151 12942 Mean cell volume of 14-week old males [fl] Hematology
X4494 12943 Sodium of 14-week old males [mM] Hematology
X633 12944 Phosphorus of 14-week old males [mM] Hematology
X2582 12945 Platelet count of 14-week old males [x10^3/ul] Hematology
X3730 12947 Red blood cell count of 14-week old males [x10^6/ul] Hematology
X2477 12951 Cholesterol (total) in serum of 14-week old males [mM] Hematology
X967 12952 Triglyceride of 14-week old males [mM] Hematology
X1933 12953 Blood proteins (total) of 14-week old males [g/l] Hematology
X2178 12954 Urea of 14-week old males [mM] Hematology
X569 12958 White blood cell count of 14-week old males [x10^3/ul] Hematology
X4275 12979 Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males and females ( DBA/2J winsorized from 89.37 +/- 10.96 to 8 Hematology
X3721 12984 Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult females (associated with GenEx EtOH liver gene expression) [U/L Hematology
X3171 12985 Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males (BXD16 winsorized from 158 +/- 32 to 92 and DBA/2J from 1 Hematology
X61 13034 Transthyretin protein serum band (prealbumin, Pre locus) detected by acylamide electrophoresis in adult males [a-genotype of DBA/2J with band is coded as 1, o-genotype without band is coded as -1] Hematology
X4803 15798 Bilirubin, fasted state, chow diet, males [umol/L] Hematology
X2552 15816 Bilirubin, fasted state, high fat diet, males [umol/L] Hematology
X46 15868 Nucleated red blood cells, chow diet, males [%] Hematology
X2444 15875 Nucleated red blood cells, chow diet, males [10^3/uL] Hematology
X47 15912 Nucleated red blood cells, high fat diet, males [%] Hematology
X48 15919 Nucleated red blood cells, high fat diet, males [10^3/uL] Hematology
X1553 16659 C16:1-carnitine_HFD for 20 weeks [nmol/ml] Hematology
X2158 16794 Ratio of C14:2-carnitine/C14:1-carnitine_HFD for 20 weeks Hematology
X4552 17799 Basal glucose in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X2472 17800 Basal glucose in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X3124 17801 Cholesterol in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X3636 17802 Cholesterol in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X1566 17803 HDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X1530 17804 HDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X4924 17805 HDL in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] Hematology
X1350 17806 HDL in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] Hematology
X3700 17807 LDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X4742 17808 LDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X4306 17809 Triglycerides in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X2719 17810 Triglycerides in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X3441 17811 Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X3145 17812 Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X3379 17813 Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] Hematology
X4980 17814 Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] Hematology
X2679 17815 Lactic acid in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] Hematology
X1239 17816 Lactic acid in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] Hematology
X4422 17817 Total protein in plasma, fasted state at 29 weeks of age_CD, males [g/L] Hematology
X2810 17818 Total protein in plasma, fasted state at 29 weeks of age_HFD, males [g/L] Hematology
X3702 17819 Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X4565 17820 Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X4286 17821 Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X4232 17822 Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X917 17823 Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] Hematology
X4278 17824 Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] Hematology
X1280 17825 Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X3621 17826 Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X2056 17827 Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] Hematology
X543 17828 Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] Hematology
X179 17829 Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X181 17830 Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X740 17831 Amylase in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X808 17832 Amylase in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X2342 17833 Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_CD, males [U/L] Hematology
X2614 17834 Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] Hematology
X2884 17835 Creatinine in plasma, fasted state at 29 weeks of age_CD, males [umol/L] Hematology
X153 17836 Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] Hematology
X2675 17837 Creatinine in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] Hematology
X3501 17838 Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] Hematology
X3935 17839 Iron (Fe) in plasma, fasted state at 29 weeks of age_CD, males [umol/L] Hematology
X4421 17840 Iron (Fe) in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] Hematology
X1821 17841 Interferon-gamma (IFN-g) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X455 17842 Tumor necrosis factor-alpha (TNF, cachexin) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X1517 17843 Interleukin 15 (IL15) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X3151 17844 Monocyte chemotactic protein 1 (MCP1, CCL2) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X3491 17845 Interleukin 10 (IL10) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X2466 17846 Macrophage inflammatory protein 1-beta (MIP1B, CCL4) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X3777 17847 Macrophage inflammatory protein 1-alpha (MIP1A, CCL3) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X741 17848 Interleukin 6 (IL6) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X351 17849 Interleukin 18 (IL18) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X1781 17878 Mean corpuscular volume reticulocytes at 29 weeks of age_HFD, males [fL/RTC] Hematology
X404 17850 Regulated and normal T cell expressed and secreted (RANTES, CCL5) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] Hematology
X872 17851 Red blood cells at 29 weeks of age_CD, males [10^6/uL] Hematology
X4616 17852 Red blood cells at 29 weeks of age_HFD, males [10^6/uL] Hematology
X1128 17853 Mature red blood cells at 29 weeks of age_CD, males [%] Hematology
X3936 17854 Mature red blood cells at 29 weeks of age_HFD, males [%] Hematology
X1100 17855 Mature red blood cells at 29 weeks of age_CD, males [10^9/L] Hematology
X3925 17856 Mature red blood cells at 29 weeks of age_HFD, males [10^9/L] Hematology
X3628 17857 Hemoglobin at 29 weeks of age_CD, males [g/dL] Hematology
X3592 17858 Hemoglobin at 29 weeks of age_HFD, males [g/dL] Hematology
X3638 17859 Hematocrit at 29 weeks of age_CD, males [%] Hematology
X5058 17860 Hematocrit at 29 weeks of age_HFD, males [%] Hematology
X783 17861 Mean corpuscular volume (MCV) at 29 weeks of age_CD, males [fL/RBC] Hematology
X1402 17862 Mean corpuscular volume (MCV) at 29 weeks of age_HFD, males [fL/RBC] Hematology
X2366 17863 Mean corpuscular hemoglobin (MCH) at 29 weeks of age_CD, males [pg/RBC] Hematology
X4071 17864 Mean corpuscular hemoglobin (MCH) at 29 weeks of age_HFD, males [pg/RBC] Hematology
X2754 17865 Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_CD, males [g/dL] Hematology
X2245 17866 Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_HFD, males [g/dL] Hematology
X3258 17867 Red blood cell hemoglobin content at 29 weeks of age_CD, males [pg/RBC] Hematology
X863 17868 Red blood cell hemoglobin content at 29 weeks of age_HFD, males [pg/RBC] Hematology
X3694 17869 Red blood cell distribution width at 29 weeks of age_CD, males [%] Hematology
X1921 17870 Red blood cell distribution width at 29 weeks of age_HFD, males [%] Hematology
X1808 17871 Hemoglobin concentration distribution width at 29 weeks of age_CD, males [g/dL] Hematology
X4200 17872 Hemoglobin concentration distribution width at 29 weeks of age_HFD, males [g/dL] Hematology
X2246 17873 Reticulocytes at 29 weeks of age_CD, males [%] Hematology
X3420 17874 Reticulocytes at 29 weeks of age_HFD, males [%] Hematology
X1256 17875 Reticulocytes at 29 weeks of age_CD, males [10^9/L] Hematology
X3755 17876 Reticulocytes at 29 weeks of age_HFD, males [10^9/L] Hematology
X4415 17877 Mean corpuscular volume reticulocytes at 29 weeks of age_CD, males [fL/RTC] Hematology
X1399 17908 Mean platelet mass at 29 weeks of age_HFD, males [pg/PLT] Hematology
X2779 17879 Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_CD, males [g/dL] Hematology
X4659 17880 Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_HFD, males [g/dL] Hematology
X1276 17881 Red cell hemoglobin content reticulocytes at 29 weeks of age_CD, males [pg/RTC] Hematology
X3879 17882 Red cell hemoglobin content reticulocytes at 29 weeks of age_HFD, males [pg/RTC] Hematology
X3789 17883 Mature reticulocytes at 29 weeks of age_CD, males [%] Hematology
X1398 17884 Mature reticulocytes at 29 weeks of age_HFD, males [%] Hematology
X773 17885 Mature reticulocytes at 29 weeks of age_CD, males [10^9/L] Hematology
X4959 17886 Mature reticulocytes at 29 weeks of age_HFD, males [10^9/L] Hematology
X1816 17887 Medium maturity reticulocytes at 29 weeks of age_CD, males [%] Hematology
X3125 17888 Medium maturity reticulocytes at 29 weeks of age_HFD, males [%] Hematology
X2238 17889 Medium maturity reticulocytes at 29 weeks of age_CD, males [10^9/L] Hematology
X1220 17890 Medium maturity reticulocytes at 29 weeks of age_HFD, males [10^9/L] Hematology
X2928 17891 Immature reticulocytes at 29 weeks of age_CD, males [%] Hematology
X437 17892 Immature reticulocytes at 29 weeks of age_HFD, males [%] Hematology
X4578 17893 Immature reticulocytes at 29 weeks of age_CD, males [10^9/L] Hematology
X4231 17894 Immature reticulocytes at 29 weeks of age_HFD, males [10^9/L] Hematology
X1464 17895 Platelets at 29 weeks of age_CD, males [10^3/uL] Hematology
X2359 17896 Platelets at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4864 17897 Mean platelet volume at 29 weeks of age_CD, males [fL/PLT] Hematology
X3233 17898 Platelet volume at 29 weeks of age_HFD, males [fL/PLT] Hematology
X577 17899 Platelet distribution width at 29 weeks of age_CD, males [%] Hematology
X2454 17900 Platelet distribution width at 29 weeks of age_HFD, males [%] Hematology
X4165 17901 Plateletcrit at 29 weeks of age_CD, males [%] Hematology
X3604 17902 Plateletcrit at 29 weeks of age_HFD, males [%] Hematology
X4253 17903 Platelet component concentration at 29 weeks of age_CD, males [g/dL] Hematology
X3433 17904 Platelet component concentration at 29 weeks of age_HFD, males [g/dL] Hematology
X4941 17905 Platelet component distribution width at 29 weeks of age_CD, males [g/dL] Hematology
X4266 17906 Platelet component distribution width at 29 weeks of age_HFD, males [g/dL] Hematology
X4360 17907 Platelet mass at 29 weeks of age_CD, males [pg/PLT] Hematology
X4028 10186 Syngeneic breast cancer tumor growth, day 20 [mm3] Immune
X4743 17909 White blood cells at 29 weeks of age_CD, males [10^3/uL] Hematology
X4432 17910 White blood cells at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4280 17911 Neutrophils at 29 weeks of age_CD, males [%] Hematology
X4242 17912 Neutrophils at 29 weeks of age_HFD, males [%] Hematology
X4954 17913 Lymphocytes at 29 weeks of age_CD, males [%] Hematology
X4737 17914 Lymphocytes at 29 weeks of age_HFD, males [%] Hematology
X3679 17915 Monocytes at 29 weeks of age_CD, males [%] Hematology
X4245 17916 Monocytes at 29 weeks of age_HFD, males [%] Hematology
X4839 17917 Eosinophils at 29 weeks of age_CD, males [%] Hematology
X5078 17918 Eosinophils at 29 weeks of age_HFD, males [%] Hematology
X2142 17919 Basophils at 29 weeks of age_CD, males [%] Hematology
X2849 17920 Basophils at 29 weeks of age_HFD, males [%] Hematology
X4909 17921 Large unknown cells at 29 weeks of age_CD, males [%] Hematology
X4317 17922 Large unknown cells at 29 weeks of age_HFD, males [%] Hematology
X3757 17923 Neutrophils at 29 weeks of age_CD, males [10^3/uL] Hematology
X4734 17924 Neutrophils at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4921 17925 Lymphocytes at 29 weeks of age_CD, males [10^3/uL] Hematology
X4322 17926 Lymphocytes at 29 weeks of age_HFD, males [10^3/uL] Hematology
X2841 17927 Monocytes at 29 weeks of age_CD, males [10^3/uL] Hematology
X481 17928 Monocytes at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4694 17929 Eosinophils at 29 weeks of age_CD, males [10^3/uL] Hematology
X5079 17930 Eosinophils at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4344 17931 Basophils at 29 weeks of age_CD, males [10^3/uL] Hematology
X5055 17932 Basophils at 29 weeks of age_HFD, males [10^3/uL] Hematology
X3928 17933 Large unknown cells at 29 weeks of age_CD, males [10^3/uL] Hematology
X3950 17934 Large unknown cells at 29 weeks of age_HFD, males [10^3/uL] Hematology
X4257 17968 Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males [pg/ul] Hematology
X2763 17970 Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult females [pg/ul] Hematology
X2790 17972 Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult females [units] Hematology
X4033 17973 Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult males and females [pg/ul] Hematology
X2761 17974 Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males and females [pg/ul] Hematology
X3579 17975 Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males and females [units] Hematology
X1273 10187 Growth of syngeneic breast cancer tumors day 25 [mm3] Immune
X1540 10034 Salmonella typhimurium bacterial strain LT2-Z growth from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3, filled circles) [log10 CFU] Immune
X844 10035 Salmonella typhimurium bacterial strain WB500 from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3 open circles) [log10 CFU] Immune
X79 10036 Salmonella typhimurium bacterial strain SR-11, net growth in livers and spleens 6 days after inoculation with 10^2 CFU (figure 5, triangles, Itk/Nramp1/Slc11a1-associated) [log10 CFU] Immune
X1298 10043 Ectromelia virus-induced mortality in males [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] Immune
X3912 10044 Ectromelia virus-induced mortality [3 = resistant, 1 = both intermediate and susceptible, ordinal scale] Immune
X321 10056 Hematopoietic stem cell pool size, cobblestone area-forming cells per 100,000 bone marrow cells [n] Immune
X746 10058 Peripheral blood lymphocytes, percentage of B cells [B220 %] Immune
X3210 10059 Peripheral blood lymphocytes, percentage of CD4+ T cells [%] Immune
X3868 10060 Peripheral blood lymphocytes, percentage of CD8+ T cells [%] Immune
X4584 10061 Polymorphonuclear leukocyte number (PMN) after aerosolized LPS exposure [PMN/ml (x103)] Immune
X1795 10062 Tumor necrosis factor (TNF)-alpha level in lung after aerosolized lipopolysaccharide (LPS) exposure [pg/ml] Immune
X4950 10113 Proliferative activity of hematopoietic stem cells, quiescent stem cells in aged mice, cobblestone area forming cells (CAFC) at day 35 in culture, frequency in bone marrow [CAFC per 10e5 bone marrow cells] Immune
X1762 10114 Proliferative activity of hematopoietic stem cells, quiescent HSCs in aged mice, cobblestone area forming cells (CAFC) on day 35, frequency in bone marrow [CAFC per 10e5 bone marrow cells] Immune
X4880 10115 Stem cell cycling, change in day 7 cobblestone area forming cell (CAFC) frequency during aging [%CAFC] Immune
X4430 10116 Proliferative activity of hematopoietic stem cells, day 21 cobblestone area forming cell (CAFC) frequency change [% CAFC] Immune
X3793 10117 Proliferative activity of hematopoietic stem cells, change in quiescent HSC percentage (cobblestone area-forming cells day 35 of culture) at 20 months [% CAFC] Immune
X4858 10118 Stem cell frequency, cobblestone area-forming cell assay count (CAFC) on day 35 [CAFC per 10e5 bone marrow cells] Immune
X2228 10119 Proliferative activity of hematopoietic stem cells on day 7 in culture [% CAFC] Immune
X312 10150 Thymic T-cell proliferative unresponsiveness (anergy) to anti-CD3-induced proliferation (chemokine-associated) [units] Immune
X3509 10179 Metastasis of implanted breast tumor in lymph node, cases with tumor metastasis [n] Immune
X3453 10180 Metastasis of implanted breast tumor in pancreas, cases with tumor metastasis [n] Immune
X3317 10181 Necrosis of implanted breast tumor [n] Immune
X2542 10182 Syngeneic breast tumor growth, number of cases with tumor metastasis [n] Immune
X2935 10183 Syngeneic breast cancer tumor growth, day 5 [mm3] Immune
X3791 10184 Growth of syngeneic breast cancer tumors day 10 [mm3] Immune
X3813 10185 Growth of syngeneic breast cancer tumors day 15 [mm3] Immune
X4364 10206 Granulocyte colony stimulating factor (G-CSF) induced progenitor cell mobilization from bone marrow to blood [PB-CFC/ul] Immune
X655 10207 Hematopoietic stem cell and progenitor cell proliferative capacity (Lin-Sca1++ cells from femur bone marrow), in vitro assay of cells from 2-3 month old females in response to KL, flt3L, and TPO (Figure 3A of paper) [n Immune
X790 10208 Hematopoietic stem cells and progenitor cells, numbers of Lin-Sca1++ cells at 2 months of age in females (Figure 3B of paper) [n] Immune
X2019 10209 Relative fraction of hematopoietic stem cells and progenitor cells (Lin-Sca1++) from bone marrow in 2-3 month old females (Figure 3C of paper) [%] Immune
X4558 10210 Hematopoietic stem cells and progenitor cells in femur bone marrow, percentage of c-kit-postiive cells to c-kit-ngative cells among Lin-Sca1++ cells in 2-month old femaies (Figure 3d of paper) [%] Immune
X4648 10211 Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (Fig 2A of paper) [n per well] Immune
X4896 10212 Percentage of hematopoietic stem cells and progenitor cells in femur bone marrow (lin-Sca1++ c-kit+) at 18 months of age (Figure 2B of paper) [%] Immune
X1887 10213 Proliferative capacity in vitro of bone marrow stem and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age in response to KL, flt3L and TPO (figure 2C of paper) [n cells] Immune
X1493 10214 Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (additional data not included in paper) [n cells total] Immune
X1644 10215 Hematopoietic stem cell and progenitor cell number (lin-Sca1++ c-kit+ cells) from femur bone marrow of females a 18 months (confirm) (unpublished additional data) [n cells] Immune
X4249 10216 Proliferative capacity, number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2, 0.01 ng/ml) at 18 months of age (confirm) (unpublished additiona Immune
X3015 10217 Proliferative capacity, effect of TGF-beta2 stimulation (0.1 ng/ml) on numbers of lin-Sca1++ c-kit+ cells (unpublished additional data) [% increase] Immune
X3046 10218 Proliferative capacity change, difference between old (18 months) and young (2 months) on number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2 Immune
X2592 10219 Percentage of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow [%] Immune
X145 10225 T-cell proliferative response (age-related decline), concavalin-A induced thymic T-cell response at 22-month-old in females (average of days 2 and 4)[unit] Immune
X4835 10226 Age-related T-cell decline, percentage of CD4-negative CD8-negative DN cells in thymus [%] Immune
X4876 10227 Age-related T-cell decline, percent of CD4-CD8 double positive cells in thymus [%] Immune
X3539 10228 T-cell decline during aging, percentage of CD25-negative/CD44-positive double negative (CD4(-)CD8(-)) cells in thymus at 22 months [%] Immune
X4788 10229 Age-related T-cell decline, percentage of CD25-positive CD44-negative DN cells in thymus [%] Immune
X1950 12907 Body weight at echocardiography of 17-week old males [g] Morphology
X4228 10230 Age-related T-cell decline, percentage of CD25-CD44 double negative thymocytes at 22 months in females [%] Immune
X4821 10231 Thymus involution, age-related rate of decline measured as involution slope (-beta 1x10^4) Immune
X2962 10232 Thymocyte count in young adult mice, initial [Beta 0] Immune
X3160 10233 Thymocyte count, projected at 60 days [units] Immune
X86 10235 Proliferation of T cell clone (JTL-G12 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] Immune
X223 10236 Proliferation of T cell clone (JTL-G12 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] Immune
X75 10237 Proliferation of T cell clone (JTL-G12.8 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] Immune
X175 10238 Proliferation of T cell clone (JTL-G12.8 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] Immune
X4042 10355 Airway inflammatory response to ozone (2 ppm for 3 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after acute exposure [number of PMNs x10^3] Immune
X2028 10356 Airway inflammatory response to ozone (0.30 ppm for 48 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after exposure [n PMNs x10^3] Immune
X1150 10361 Progenitor cell proliferation in young mice (2 months of age), effect of TGFB2 (0.1 ng/ml) on the proliferation of lin-Sca1++kit+ cells relative to control without TGFB2 [%] Immune
X4983 10370 Hepatocellular carcinoma tumor multiplicities induced by N,N-diethylnitrosamine (DEN 0.01 ml/g, ip at postnatal day 12), mean tumor multiplicity in liver at 32 weeks in male [n] Immune
X1897 10372 Tumor necrosis factor (TNF)-induced hypothermia [degree C] Immune
X339 10373 Tumor necrosis factor (TNF) lethal shock, induction of serum interleukin 6 (IL-6) cytokine after injection [ng/ml] Immune
X937 10374 Tumor necrosis factor (TNF) lethality after injection [%] Immune
X2851 10403 Theiler's murine encephalomyelitis virus (TMEV) spinal cored demyelination susceptibility (excludes strains with B allele at H2 locus) [% affected] Immune
X2352 10404 Theiler's murine encephalomyelitis virus (TMEV, dermal injection), delayed-type hypersensitivity (DTH) response measured as ear swelling [inch x 1E-3] Immune
X3980 10427 xenotropic MuLV envelope-related cell-surface antigens (XenCSA) levels on thymus cells measured as mean fluorescence value (sum of products of each channel number times n cells in that channel divided by n cells counted) Immune
X856 10428 lymphocyte major glycoprotein (gp70) xenotropic leukemia virus envelope-related cell-surface antigen (XenCSA) level measured as mean fluorescence value (sum of products of each channel number times the number of spleen cells in that channel Immune
X4925 10433 ;Immune complex deposits in kidney immunized with the 16/6 Id [0=no immune complexes;; 1=1-5 immune complex deposits;; 2=5-20 immune complex deposits;; 3=20-50 immune complex deposits;; 4=50 immune complex deposits]; Immune
X2469 10439 Lung, Airway bronchial constrictor response after exposure to atracurium, airway pressure time index [cmH2O/s] Immune
X487 10463 Thymus to body size ratio [x10^3] Immune
X1868 13008 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 4 after infection in 9-14 week-old females [%] Immune
X212 10464 Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 positive T cells) [%] Immune
X149 10465 Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 positive T cells) [%] Immune
X109 10466 Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 negative T cells) from Fig 4 y-axis [%] Immune
X3349 10467 Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 negative T cells) from Fig 4 x-axis [%] Immune
X1539 10508 V beta 3+ T cells in lymph nodes [%] Immune
X94 10591 Murine cytomegalovirus (MCMV) titer in spleen 4 days after infection with 5X10^4 PFU (KLRA complex) [log10 burden] Immune
X2650 10592 Anergy measured by footpad thickness resulting from BCG injection [mm] Immune
X3710 10656 LacZ expression 7 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] Immune
X4993 10657 LacZ expression 21 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] Immune
X5037 10658 LacZ expression 30 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] Immune
X4994 10659 LacZ expression 50 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] Immune
X4857 10660 Cytotoxicity in spleen T cells 7 days after 5x109 PFU AdLacZ i.v injection [%] Immune
X5041 10661 Cytotoxicity in spleen T cells 21 days post 5x109 PFU AdLacZ i.v injection [%] Immune
X4726 10662 Cytotoxicity in spleen T cells 30 days post 5x109 PFU AdLacZ i.v injection [%] Immune
X2826 10663 Cytotoxicity in spleen T cells 50 days post 5x109 PFU AdLacZ i.v injection [%] Immune
X608 10664 Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interferon gamma (IFNG) cytokine expression [ng/ml/] Immune
X3720 10665 Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as tumor necrosis factor alpha (TNFa) cytokine expression [pg/ml] Immune
X1543 10666 Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interleukin 6 (IL-6) cytokine expression [pg/ml] Immune
X2216 10687 Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU), fraction dead 21 days after infection [ratio] Immune
X4467 10688 Myoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection gross pulmonary lesions [burden] Immune
X3249 10689 Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway exudate [units] Immune
X3388 10690 Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway epithelial hyperplasia Immune
X3962 10691 Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway lymphoid hyperplasia Immune
X1345 10692 Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, alveolar exudate [units] Immune
X4618 10695 Lung inflammatory response, pulmonary granulomatous inflammation induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (BCG) [units] Immune
X4144 10696 Spleen weight, splenomegaly induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (iv injection in oil and saline) (BCG) [mg] Immune
X584 10697 Autoimmune disease, spontaneous development of immune response, anti-DNA antibodies sera titers, 13 month females (Fig 7 from Mountz et al., 2005) [natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4, ln of 0 Immune
X3558 10698 Autoimmune disease, rheumatoid factor sera titers, 13 month females (natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4) Immune
X442 10711 Phenyloxazolone hapten-induced Igh-Ox antibody marker level (public idiotype)[units] Immune
X4252 10712 Skin tumors after initiation with N-methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [n per case] Immune
X3436 10715 Sendai virus lethality with 1.0 TCID50 [% mortality] Immune
X3362 10716 Resistance to lymphoma tumors induced by ESb DBA/2 (H-2d) cell transplant [%] Immune
X3175 10736 Skin tumor incidence following initiation with N-Methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [% mice] Immune
X5072 10766 Autoimmune disease, spontaneous development of immune response, IgG1-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X5038 10767 Autoimmune disease, spontaneous development of immune response, IgG2a-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X5082 10768 Autoimmune disease, spontaneous development of immune response, IgG2b-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X3065 10769 Autoimmune disease, spontaneous development of IgM-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X4666 10770 Autoimmune disease, spontaneous development of immune response, IgG1-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X4481 10771 Autoimmune disease, spontaneous development of immune response, IgG2a-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X5070 10772 Autoimmune disease, spontaneous development of immune response, IgG2b-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X2010 10773 Autoimmune disease, spontaneous development of immune response, IgM-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] Immune
X5076 10774 IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, day 0 baseline [ELISA OD 450] Immune
X941 10775 IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 14 [ELISA OD 450] Immune
X891 10776 IgG2b anti-AAV2 (adeno-associated virus type 2) immune response following injection of 3xE11 vector genomes vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, on day 42 [ELISA OD 450] Immune
X2804 12908 Body weight of 18-week old males [g] Morphology
X585 10777 IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 120 [ELISA OD 450] Immune
X412 10778 IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3xE11 vector genomes (vg) /mouse AAV2-(ApoE)4/hAAT-cF.IX on day 180 [ELISA OD 450] Immune
X1867 10779 IgG1 isotype-specific anti-cF.IX (coagulation Factor IX) response following injection of 3e11 vg/mouse AAV2-cF.IX [ELISA OD 450 (x 10^4)] Immune
X4140 10780 Antibody IgG1 response following iv injection of canine coagulation factor IX (cF.IX, 3E11 vg/mouse) [ng/ml] Immune
X2361 10784 Autoimmune disease, spontaneous development of generalized Ig to anti-DNA in 13-month-old mice [natural log of total Ig to anti-DNA (ELISA OD 450 x 10^4)] Immune
X3580 10785 Autoimmune disease, spontaneous development of generalized autoimmunity measured as ratio of Ig to rheumatoid factor (RF) in 13-month-old mice [ratio, natural log of total Ig to RF (ELISA OD 450 x 10^4)] Immune
X157 10801 Streptococcus pyogenes disease severity, corrected relative survival index (Fig 1A, residuals after correction for age, sex, body weight and log inoculum, with added strains BXD76 and BXD80) [-1 = high susceptible, +1 is Immune
X77 10806 Chlamydia psittaci (6BC) infection response (10^4 IFU ip), survival index at 11 days in 2-4 month males [mean score, 0=resistant, 1=weight loss and all survive, 2=weight loss some survive, 3=no survival] Immune
X2838 10811 Iron level in spleen of males and females [ug/g] Immune
X4606 10813 Iron level in spleen of females [ug/g] Immune
X4830 10818 Iron level in spleen of males [ug/g] Immune
X136 10836 Streptococcus pyogenes disease severity, corrected relative survival index (differs from Fig 1A slightly, residuals after correction for age, sex, body weight and log inoculum, with added strain BXD80) where -1 means hig Immune
X388 10855 Chlamydia psittaci (6BC) infection response (10^4 IFU ip), weight loss ratio at 11 days compared to baseline in 2-4 month males [ratio] Immune
X657 10865 H5N1 influenza A virus mortality rate 30 days after infection (10^4 EID-50 of HK213 virus in 30 microliters saline) [% death] Immune
X893 10866 H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30] Immune
X2409 10890 Hematopoietic stem cell number (cobblestone-area-forming cells per femur at 35 days of age from 3 females, also previously published) [n] Immune
X4258 10954 Hepatocellular carcinoma tumor multiplicity in liver of males after infection with 0.01 ml/g body wt N,N-diethylnitrosamine [n] Immune
X4055 11001 Immune response to bacterial LPS, polymorphonuclear macrophage after 4 hr acute, bronchial lavage [1000/ml] Immune
X1980 11021 Streptococcus pyogenes (Group A streptococcal infection) dissemination to spleens, 24 h post-infection (Fig 1C) [CFU/ml] Immune
X236 11022 Streptococcus pyogenes (Group A streptococcal infection) sepsis bacteremia 24 h post-infection corrected for age, sex, body weight, log inoculum (Fig 1B) [corrected log CFU/ml] Immune
X107 11025 Chlamydia psittaci (6BC) infection response (10^4 IFU ip), pathogen load in peritoneal cavity at 30 days among surviving 3-5 month males (subset of cases) [log ng of DNA] Immune
X803 11026 Chlamydia psittaci (6BC) infection response (10^4 IFU ip), spleen weight at 30 days among surviving animals, 2-4 months males (subset of cases from Miyiari 2007) [gm] Immune
X2932 12488 Spleen weight of 120-day-old females fed 3 ppm Fe diet [g] Immune
X3943 12489 Iron level in spleen of 120-day-old females fed 3 ppm Fe diet [ug/g] Immune
X2947 12496 Spleen weight of 120-day-old males fed 3 ppm Fe diet [g] Immune
X5016 12497 Iron level in spleen of 120 day old males fed 3 ppm Fe diet [ug/g] Immune
X4371 12504 Spleen weight of 120-day-old females fed 270 ppm iron (Fe) diet [g] Immune
X5073 12505 Iron level in spleen of 120-day-old females fed 270 ppm Fe diet [ug/g] Immune
X1995 12512 Spleen weight of 120-day-old males fed 270 ppm Fe diet [g] Immune
X3520 12513 Iron level in spleen of 120 day old males fed 270 ppm Fe diet [ug/g] Immune
X3588 12520 Spleen weight of 120-day-old males and females fed 3 ppm Fe diet [g] Immune
X2896 12521 Iron level in spleen of 120 day old males and females fed 3 ppm Fe diet [ug/g] Immune
X2789 12531 Spleen weight of 120-day-old males and females fed 270 ppm Fe diet [g] Immune
X5065 12532 Iron level in spleen of 120 day old males and females fed 270 ppm Fe diet [ug/g] Immune
X4013 12603 Peripheral blood lymphocytes, CD4+/CD8+ T cell ratio, males at 3-5 month [ratio] Immune
X587 12667 Ectromelia virus survival over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.7 days/unit] Immune
X884 12668 Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence Immune
X1274 12669 Ectromelia virus euthanasia scale over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [-1 is survival, +2 is rapid Immune
X693 12670 Ectromelia virus measure of disease onset, day of maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and Immune
X378 12671 Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for s Immune
X521 12672 Ectromelia virus survival over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.33 days/unit] Immune
X4331 12673 Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence of l Immune
X1139 12674 Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, Immune
X2346 12675 Ectromelia virus measure of disease onset measured by the day of maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, Immune
X2730 12676 Cowpox virus survival over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [~2.67/unit] Immune
X1307 12677 Cowpox virus severity of disease measured by the maximum clinical score over two weeks after a 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age, and body Immune
X3687 12678 Cowpox virus measure of disease onset measured by the day of maximum clinical score over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age Immune
X4349 12679 Cowpox virus maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [scaled deg C where -0.5 is > Immune
X3431 12680 Cowpox virus measure of disease onset measured by the day of maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, a Immune
X2133 12681 Cowpox virus maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight at time of inoculation [scaled % l Immune
X4991 12682 Cowpox virus measure of disease onset measured by the day of maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age an Immune
X387 12683 Ectromelia virus mortality score (combined data from Brownstein 1999 and Rice et al. 2010) [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] Immune
X2505 12702 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) footpad swelling, 3 weeks post infection in females (BXD80 winsorized from 196 to 120) [% of C57BL/6 control] Immune
X477 12703 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), parasite burden in feet 3 weeks post infection in females [% of C57BL/6 control] Immune
X2739 12704 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) Interferon-gamma from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X1375 12705 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), granulocyte colony-stimulating factor (G-CSF, CSF3, Chr 11 at 98.6 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 con Immune
X2087 12706 Leishmania major (footpad injection of 5 million promastigotes at 7 weeks) granulocyte macrophage colony-stimulating factor (GM-CSF) level from draining lymph node, 3 weeks after infection in females (Luminex assay) [% Immune
X3112 12707 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X593 13009 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 5 after infection in 9-14 week-old females [%] Immune
X894 12708 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), interleukin-1 beta level (IL1B, Chr 2 at 129 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 control] Immune
X5027 12709 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X3459 12710 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-3 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X2946 12711 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-4 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X4926 12712 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-5 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X2887 12713 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-6 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X3496 12714 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X3507 12715 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-13 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X1631 12716 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-17 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X1917 12717 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) IP-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X2532 12718 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X927 12719 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), chemokine (C-X-C motif) ligand 1 level (CXCL1, KC, Chr 5 at 91 Mb) from draining lymph node 3 weeks post infection in females [% of C57BL/6 contro Immune
X2339 12720 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) LIF from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X4118 12721 Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), monocyte chemoattractant protein-1 (MCP1) level from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] Immune
X1819 12723 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X4260 12724 Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), macrophage inflammatory protein-1 beta (MIP1B) from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] Immune
X544 13010 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 6 after infection in 9-14 week-old females [%] Immune
X1770 12725 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) MIG alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X2431 12726 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) RANTES from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X815 12727 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), tumor necrosis factor alpha level (TNFA, Chr 17 at 35 Mb) from draining lymph node 3 weeks post infection in females using Luminex assay Immune
X1045 12728 Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), vascular endothelial growth factor (VEGF) level from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] Immune
X3733 12968 Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC) in 7-12 week-old males (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] Immune
X670 12969 Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old females (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] Immune
X216 12971 TNFa cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] Immune
X1144 12972 MCP1 cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] Immune
X194 12973 Interferon alpha (IFNa) cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] Immune
X4722 12994 Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old males (1=resistant and 0= susceptible)[survival fraction] Immune
X2266 12995 Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old females (1=resistant and 0= susceptible)[survival fraction] Immune
X419 12996 H1N1 (PR8) influenza A virus (2x10E3 FFU), mean time to death after infection in 9-14 week-old females [days] Immune
X1797 13000 H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 11 after infection in 9-14 week-old females [%] Immune
X217 13001 H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 7 after infection in 9-14 week-old females [%] Immune
X511 13002 H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 8 after infection in 9-14 week-old females [%] Immune
X1071 13003 H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 9 after infection in 9-14 week-old females [%] Immune
X1618 13004 H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 10 after infection in 9-14 week-old females [%] Immune
X1832 13005 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 1 after infection in 9-14 week-old females [%] Immune
X2637 13006 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 2 after infection in 9-14 week-old females [%] Immune
X2468 13007 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 3 after infection in 9-14 week-old females [%] Immune
X1481 13011 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 7 after infection in 9-14 week-old females [%] Immune
X2558 13012 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 8 after infection in 9-14 week-old females [%] Immune
X2275 13013 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 9 after infection in 9-14 week-old females [%] Immune
X1586 13014 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 10 after infection in 9-14 week-old females [%] Immune
X2030 13015 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 11 after infection in 9-14 week-old females [%] Immune
X1288 13016 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 12 after infection in 9-14 week-old females [%] Immune
X1573 13017 H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 13 after infection in 9-14 week-old females [%] Immune
X999 13043 Coccidioides immitis (Valley fever, San Joaquin California disease fungus, Coccidioidomycosis) susceptibility after an IP injection (500 - 800 CFU of the RS strain) in 7 to 12-week-old females, 10 per Immune
X674 13507 Burkholderia pseudomallei (126b) infection response (50 CFU intranasal), survival in males, [1=resistant, 0=sensitive] Immune
X600 14309 Serum glucose (unfasted) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [mg/dL serum) Immune
X4075 14310 Candida albicans titer in brain at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] Immune
X706 14312 Candida albicans titer in kidney (log) at 72 h after inoculation with 1 x 10^6 cfu (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] Immune
X4057 14316 lipocalin-2 (LCN-2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X4281 14317 Interleukin-6 (IL-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein] Immune
X1717 14318 G-CSF (granulocyte colony stimulating factor) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X2668 14319 IP-10 (Interferon gamma-induced protein 10 or CXLC10) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, kidney] Immune
X4965 14320 MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X1829 14321 ;\KC (CXCL1;; keratinocyte-derived chemokine at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X1769 10175 Ethanol response (2 g/kg ip), rate of ethanol clearance [mg/ml/hr] Metabolism
X3772 14322 MCP-1 (CCL2 or monocyte chemotactic protein-1) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X2894 14323 TNF-a at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] Immune
X2654 14324 temperature during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C) Immune
X3321 14326 Temperature during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] Immune
X4463 14328 Temperature during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] Immune
X4428 14330 locomotor activity during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] Immune
X3848 14331 locomotor activity during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] Immune
X4793 14332 locomotor activity during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] Immune
X2806 14333 locomotor activity during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] Immune
X1353 14334 locomotor activity during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] Immune
X1094 14335 Locomotor activity 60-72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] Immune
X2674 14338 G-CSF (granulocyte colony stimulating factor) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] Immune
X2035 14339 IL-6 (interleukin-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] Immune
X2179 14340 ;\KC (CXCL1;; keratinocyte-derived chemokine) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]\ Immune
X3406 14341 IP-10 (Interferon gamma-induced protein 10 or CXLC10) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, log, kidney] Immune
X491 14342 Lipocalin-2 (LCN-2) level in kidney 72 h after inoculation with 1 x 10^6 CFU Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] Immune
X2951 10176 Ethanol response (3 g/kg ip), rate of clearance, beta [mg/ml/hr] Metabolism
X1422 14343 MCP-1 (CCL2 or monocyte chemotactic protein-1) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] Immune
X2308 14344 MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidn Immune
X634 14345 TNF-a (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] Immune
X4984 14349 locomotor activity (log) during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline. log] Immune
X4711 14350 locomotor activity (log) during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] Immune
X4816 14351 locomotor activity (log) during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] Immune
X2284 14352 locomotor activity (log) during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] Immune
X1588 14353 Locomotor activity (log) during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] Immune
X2920 14401 Acinetobacter baumannii infection, bronchoalveolar lavage (BAL) lung lymphocyte cell number following (BXD65 winsorized from 47.5 to 26.0) [units/ul] Immune
X1639 14402 Bronchoalveolar lavage (BAL) lung lymphocyte cell number following infection with Acinetobacter baumannii [units/ul] Immune
X264 14783 Chlamydia muridarum upper genital tract disease severity (endometrium, uterine horn) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe] Immune
X414 14785 Chlamydia muridarum upper genital tract disease severity (oviduct) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe disease] Immune
X3266 14807 Susceptibility to Staphylococcus aureus, colony forming units (CFU) in blood 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] Immune
X2350 14808 Susceptibility to Staphylococcus aureus, colony forming units (CFU) in kidney 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] Immune
X4506 14809 Susceptibility to Staphylococcus aureus, colony forming units (CFU) in liver 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] Immune
X1663 14810 Susceptibility to Staphylococcus aureus, colony forming units (CFU) in heart 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] Immune
X3981 14811 Susceptibility to Staphylococcus aureus, mean time of death in days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [days] Immune
X1194 14812 Susceptibility to Staphylococcus aureus, survival 10 days after infection with 10E5 colony forming units (CFU) in 10 to 14 day-old females [%] Immune
X1970 14813 Susceptibility to Staphylococcus aureus, % survival after 4 days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [%] Immune
X1891 14814 Mycobacterium tuberculosis (H37Rv, 100 colony forming units (CFU)) response, bacterial load in lung 21 days after aerosol infection in 12-23 week-old females [linear CFU/lung/1000] Immune
X575 14815 Linear bacterial load in lung 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / lung / 10000] Immune
X4934 14816 Linear bacterial load in spleen 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / spleen / 100] Immune
X3526 14817 Linear bacterial load in spleen 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / spleen / 1000] Immune
X1834 14818 Linear bacterial load in liver 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / liver / 10] Immune
X5053 14819 Linear bacterial load in liver 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / liver / 100] Immune
X3128 14820 Quantity of lung pathology 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [quantitative score (10 lowest - 70 highest)] Immune
X3989 14821 Quantity of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [quantitative score (10 lowest - 70 highest)] Immune
X1642 14822 Lung weight/body weight 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [lung weight/body weight * 10000] Immune
X4891 14823 Lung weight/body weight 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [lung weight/body weight * 10000] Immune
X2495 14824 Linear median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days] Immune
X3416 14825 Bacterial load in lungs 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [log10 CFU / lung * 100] Immune
X2967 14826 Bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [log10 CFU / lung * 100] Immune
X4933 14827 Normalized bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ratio CFU BXD / CFU C57BL/6J * 100] Immune
X2343 15120 CD44+ Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4086 14828 Quality of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ordinal scale (10 = normal, 20 = intermediate, 30 = severe)] Immune
X4997 14829 Body weight 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [g] Immune
X2402 14830 Mean moribund body weight after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [g * 10] Immune
X4427 14831 Mean temperature 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [deg C * 10] Immune
X4923 14832 Mean moribund temperature after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [deg C * 10] Immune
X3195 14833 Normalized median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [ratio survival time BXD / survival time C57BL/6J * 100] Immune
X4194 14834 Median survival time in log10 after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days in log10 * 100] Immune
X1198 15107 CD3+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X1041 15108 CD3+CD4+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2992 15109 CD3+CD8a+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2508 15110 CD25+ cells as a percentage of CD3+ CD4+ in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2020 15111 CD3+ gamma/delta TCR+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2325 15112 Ly6C+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X1895 15113 CD62L+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X126 15114 CD44+ effector-memory T cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (this trait maps to CD44 locus) (FACS) [%] Immune
X1945 15115 CD44+ cells as a percentage of CD3+ CD4+ without CD62L cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X991 15116 CD62L+ T cells without CD44 cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2891 15117 Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X2986 15118 CD62L+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4376 15119 CD44+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X1997 15121 CD44+ cells excluding CD62L cells as a percentage of CD8+ CD3+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X660 15122 CD62L+ cells excluding CD44 cells as a percentage of CD3+CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X3451 15123 GR-1+ CD11b+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X3969 15124 Gr-1-NKp46- CD11b+ as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4986 15125 Nkp46+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4000 15126 B cells (CD19 or B220 and IgD) as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4459 15127 CD5+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X4680 15128 IgD+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X1043 15129 B cells as a percentage of MHC class II (I/A-E) cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X1909 15130 Immune system, CD11b+ NKp46+ cells as a percentage of CD5-cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] Immune
X3655 15133 Malaria infection lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old males and females (0 = 100% resistant, 1 = 100% susceptible) [fraction of cohort that survives] Immune
X1550 15167 Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, females between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions wh Immune
X3149 15168 Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males only between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions Immune
X475 15555 Kramer RM, Lamkin T, and colleagues TAFI1 Immune
X823 15556 Kramer RM, Lamkin T, and colleagues TAFI3 Immune
X278 15557 Kramer RM, Lamkin T, and colleagues TAFI2 Immune
X347 15558 Kramer RM, Lamkin T, and colleagues TAFI4 Immune
X552 15559 Kramer RM, Lamkin T, and colleagues TAFI5 Immune
X525 15560 Kramer RM, Lamkin T, and colleagues TAFI6 Immune
X406 15561 Kramer RM, Lamkin T, and colleagues TAFI7 Immune
X1572 15562 Kramer RM, Lamkin T, and colleagues TAFI8 Immune
X1650 15563 Kramer RM, Lamkin T, and colleagues TAFI9 Immune
X782 15564 Kramer RM, Lamkin T, and colleagues TAFI10 Immune
X2684 15565 Kramer RM, Lamkin T, and colleagues TAFI11 Immune
X4530 15566 Kramer RM, Lamkin T, and colleagues TAFI12 Immune
X3561 15568 Kramer RM, Lamkin T, and colleagues, TAFI13 Immune
X2166 15569 Kramer RM, Lamkin T, and colleagues TAFI14 Immune
X331 15963 Tuberculosis, bacterial load in lung (BXD71 winsorized from 4.18 to 4.98) [log CFU] Immune
X4135 15964 Malaria susceptibility, murine Plasmodium yoelli 17 (PY17X-L) [0=resistant, 1= susceptible] Immune
X531 16185 Herpes simplex virus type 1, virulence following corneal infection, young adult male and female (combined) [percent mortality] Immune
X1506 16186 Herpes simplex virus type 1, stromal keratitis severity following corneal infection, young adult male and female (combined) [ordinal 1 t0 5 scale, 0=none, 5 = penetrating lesions] Immune
X4083 16191 Herpes simplex virus type 1, spleen weight following corneal infection, young adult female [g] Immune
X4851 16192 Herpes simplex virus type 1, spleen weight following corneal infection, young adult male [g] Immune
X5018 16193 Herpes simplex virus type 1, spleen weight following corneal infection, young adult male and female (combined) [g] Immune
X310 16194 Herpes simplex virus type 1, percent maximum weight loss following corneal infection, young adult female (combined) [max weight loss %] Immune
X203 16195 Herpes simplex virus type 1, percent weight loss following corneal infection, young adult male [max weight loss %] Immune
X133 16196 Herpes simplex virus type 1, percent weight loss following corneal infection, young adult female and male [max weight loss %] Immune
X2001 16228 Herpes simplex virus 1 (HSV-1) ocular pathogenesis, please add details on sex, innoculum, age, etc here [units] Immune
X2370 16242 Cowpox virus disease onset measured by day of max clinical score over three weeks after 10^5pfu intranasal infection, males and females between XX and XXX days of age, residuals corrected for age, sex and body weight [ Immune
X3884 16304 Herpes simplex virus type 1, serum neutralizing antibody titer in young adult males [unit] Immune
X749 16305 Herpes simplex virus type 1, serum neutralizing antibody titer in young adult females [unit] Immune
X3828 16314 serum inhibition of TSH binding to the TSHR before immunization [% inhibition] Immune
X98 16315 TBI-2x, serum inhibition of TSH binding to the TSHR 1 week after 2 immunizations with TSHR A-subunit adenovirus [% inhibition] Immune
X74 16316 Serum inhibition of TSH binding to the TSHR 4 weeks after 3 immunizations with TSHR A-subunit adenovirus in young adult females [% inhibition] Immune
X2102 16320 ELISA-2x, IgG class antibody binding to TSHR A-subunit protein in ELISA 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus [OD 490 nm] Immune
X1687 16321 ELISA-3x, IgG class antibody binding to TSHR A-subunit protein in ELISA 4 weeks after 3 immunizations with TSHR A-subunit adenovirus [OD490 nm] Immune
X215 16330 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, [1=resistant, 0=sensitive] Immune
X254 16331 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, day of death [days] Immune
X1317 16332 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 1 [% change in body weight] Immune
X1963 15733 Body temperature after 6 hours in 4 deg C chamber, high fat diet / chow diet, males [ratio] Metabolism
X1778 16333 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 2 [% change in body weight] Immune
X1308 16334 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 3 [% change in body weight] Immune
X745 16335 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 4 [% change in body weight] Immune
X1427 16343 H1N1 (PR8) influenza A virus (2x10E3 FFU), body weight loss day 3 after infection in 9-14 week-old females [%] - individual mice from RNAseq experiment (HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) Immune
X1489 16346 Herpes simplex virus type 1, serum neutralization titer following corneal infection, young adult male and female (combined) [unit] Immune
X1010 16350 Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss, first principal component, days 1-4 [% change in body weight] Immune
X798 16376 Please enter the full trait description here even BEFORE publication. Only you will see these descriptions. Immune
X3506 16377 EOMES coefficient (Malak Kotb and colleagues 2014) Please provide a full description of the trait now here with information on sex, age range, innoculum, route of infection etc. [units] Immune
X2731 16607 Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units] 3_colo_Russo Immune
X3143 16608 Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units]deltaD2-D1_colo_Russo Immune
X743 17081 Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10___16 weeks of age (scored as follows: death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index] Immune
X4894 17319 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral HA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X4802 17320 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral M gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X3699 17321 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X3830 17322 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NP gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X3263 17323 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NS gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X1939 17324 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB1 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM Immune
X3584 17325 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB2 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM Immune
X4315 17326 H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] Immune
X59 17439 Rickettsiu tsutsugamushi susceptibility (strain Gilliam, ip 100 50% mouse infectious doses, two treatments) of both sexes at 6-12 weeks-of-age (ordinal scale 0 = resistant, 1=susceptible, also see BXH RI set), maps to Gb Immune
X443 17467 Log Day 1 of counts of E coli colonization in BXD strains colon after infection with 109 cfu of E. coli strain O157:H7, isolate Tuv 86-2 (Stx2-), intra-gastric gavage, female mice, 5___7 weeks old [CFU/g feces] Immune
X958 17520 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 4 [%] Immune
X449 17521 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 3 [%] Immune
X989 17522 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 2 [%] Immune
X871 17523 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 1 [%] Immune
X106 17524 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections survival after infection corrected for strain, sex, age and body weight given as corrected relative survival index [-1.5 = high Immune
X1541 17525 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections lesion size after infection corrected for strain, sex, age and body weight given as maximum lesion area [Sq.mm] Immune
X284 17527 Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight given as principal component 1 of day 1 to da Immune
X4233 18440 Malaria susceptibility, murine Plasmodium yoelli 17X-lethal (PY17X-L) [0=100% resistant, 1= 100% susceptible] Immune
X1700 10019 Body temperature following saline injection, control for morphine response [degree C] Metabolism
X3400 10045 Body temperature (baseline control for quinpirole study) [degrees C] Metabolism
X687 10112 Life span, longevity of females (RWW winsorized outliers BXD2, BXD14, and DBA2J from 400,500, and 175 days, respectively, data originally from Gelman et al. 1988, except parental strains) [days] Metabolism
X536 10148 Life span, longevity of females (mean age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to s Metabolism
X3076 10149 Hepatic lipid peroxidation (LPO) levels in 2-month-old males [malondialdehyde (MDA)/mg] Metabolism
X261 17731 Body weight in home cage_CD, males [g] Morphology
X4553 10177 Pharmacology. Ethanol response (2 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] Metabolism
X3138 10178 Ethanol response (3 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] Metabolism
X3824 10247 Iron level in liver of males [ug/g] Metabolism
X2462 10248 Iron level in liver of females [ug/g] Metabolism
X90 10371 Cytosolic aryl-hydrocarbon receptor (AHR) protein levels in liver (fmol/mg cytosolic protein) Metabolism
X1214 10380 B-mannosidase activity in liver of females, p-nitrophenl liberated per tissue wet weight per hour at 37 deg C (Manba gene on Chr 3 at 135 Mb) [mg/gm/hr] Metabolism
X3132 10510 Ethanol response (4 g/kg ip), body temperature 120 min after injection in males [degrees C] Metabolism
X3177 10519 Body temperature baseline control before injection with ethanol (4 g/kg ip) in females [degrees C] Metabolism
X4040 10520 Body temperature baseline control before injection with ethanol (4 g/kg ip) in males [degrees C] Metabolism
X1649 10521 Ethanol response (4 g/kg ip), body temperature 120 min after injection in females [degrees C] Metabolism
X1875 10522 Body temperature baseline control before saline injection in females [degrees C] Metabolism
X4372 10812 Iron level in liver of males [ug/g] Metabolism
X4392 10821 Iron level in liver of males and females [ug/g] Metabolism
X4763 10835 Iron level in liver of females [ug/g] Metabolism
X4167 11710 Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for females [mg/dl XX min after injection] Metabolism
X5045 12490 Iron level of liver of 120-day-old females fed 3 ppm Fe diet [ug/g] Metabolism
X4310 12498 Iron level of liver of 120-day-old males fed 3 ppm Fe diet [ug/g] Metabolism
X2319 12506 Iron level in liver of 120-day-old females fed 270 ppm Fe diet [ug/g] Metabolism
X1854 12514 Iron level of liver of 120-day-old males fed 270 ppm Fe diet [ug/g] Metabolism
X5034 12522 Iron level of liver of 120-day-old males and females fed 3 ppm Fe diet [ug/g] Metabolism
X2127 12533 Iron level of liver of 120-day-old males and females fed 270 ppm Fe diet [ug/g] Metabolism
X3332 12563 Life span, longevity of males on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=116 days and BXD31=434 days are deleted outliers) Metabolism
X3309 12564 Life span, longevity of females on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=158 days and BXD31=264 days are deleted outliers) Metabolism
X4495 12684 High-dose total body gamma-irradiation survival for 12-week-old females, mean survival time (MST) after a 137-Cesium 6 Gy single exposure (LD80/30) evaluated over a 30 day post-exposure, no supportive care [resid Metabolism
X1518 12826 Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old females [mg/dl] Metabolism
X1731 12852 Food intake of 13-week old females [g/mouse] Metabolism
X3365 12856 Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old females [mg/dl] Metabolism
X3340 12857 Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old females [mg/dl] Metabolism
X3528 12858 Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old females [mg/dl] Metabolism
X3358 12859 Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old females [mg/dl] Metabolism
X2713 12860 Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old females [mg/dl] Metabolism
X4264 12867 Liver mass of 20-week old females [g] Metabolism
X508 12878 Respiratory exchange ratio (RER) of 13-week old females [ratio] Metabolism
X3446 12879 Body temperature (rectal) of 13-week old females [deg C] Metabolism
X2846 12885 Volume of CO2 production of 13-week old females [ml/kg/h] Metabolism
X3053 12886 Volume oxygen consumption of 13-week old females [ml/kg/h] Metabolism
X1210 12889 Water intake of 13-week old females [ml/mouse/unit time] Metabolism
X913 12896 Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old males [mg/dl] Metabolism
X4872 12922 Food intake of 13-week old males [g/mouse] Metabolism
X1475 12926 Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old males [mg/dl] Metabolism
X1863 12927 Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old males [mg/dl] Metabolism
X2159 12928 Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old males [mg/dl] Metabolism
X1078 12929 Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old males [mg/dl] Metabolism
X2941 12930 Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old males [mg/dl] Metabolism
X4956 12937 Liver mass of 20-week old males [g] Metabolism
X993 12948 Respiratory exchange ratio (RER) of 13-week old males [ratio] Metabolism
X4758 12949 Body temperature (rectal) of 13-week old males [deg C] Metabolism
X309 12955 Volume of CO2 production of 13-week old males [ml/kg/h] Metabolism
X966 12956 Volume oxygen consumption of 13-week old males [ml/kg/h] Metabolism
X3600 12959 Water intake of 13-week old males [ml/mouse/unit time] Metabolism
X4023 12977 Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] Metabolism
X3630 12978 Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] Metabolism
X3764 12980 Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males (associated with GenEx EtOH liver gene expression) [mg/dl] Metabolism
X2338 12981 Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] Metabolism
X3008 12983 Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] Metabolism
X3645 16924 Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CD Metabolism
X2619 13030 Vials of hepatocyte obtained per strain from first run of spring 2011 by Piedmont and Varigenix, one vial of approximately 1 million cells (the error term is 2 times the percentage of non-viable cells) [n] Metabolism
X2749 13037 Hepatocyte phase I (CYP1A) metabolic activity measured by 7-ethoxycoumarin-o-deethylase (ECOD, 7EC) consumption at 0 and 30 minutes (25 uM/sample) using cryorederived hepatocytes from young adult male liver (BXD31 winsorize Metabolism
X1694 13038 Hepatocyte phase II metabolic activity (7HC, glucuronidation and sulfation) measured by production of 7-hydroxycoumarin glucouronide at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male li Metabolism
X3854 13040 Hepatocyte viability, fraction of viable cells after rederivation relative to viable cells immediately after isolation in suspension (data from first run of spring 2011 by Piedmont and Varigenix) [ratio] Metabolism
X3780 13042 Hepatocyte phase II metabolic activity measured by 7-HCS sulfation assay at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male liver [7-HCS pmol/million cells/min] Metabolism
X3663 13542 Hepatocyte general viability at 0 hr post-thaw in suspension, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] Metabolism
X1682 13543 Hepatocyte general viability at 4 hr post-thaw on plates, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] Metabolism
X3610 13552 Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells corrected for DNA content 31.5 hr after seeding with 20,000 cells, young adult male liver (BXD15 winsorized from 223 to 160) [ Metabolism
X1513 13553 Hepatocyte plating efficiency, cells per control wells (DNA assay) 31.5 hr after seeding with 20,000 cells/well, young adult male liver [ng/ml] Metabolism
X714 13554 Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells (uncorrected for viable cell number) 33 hours after seeding with 20,000 cells, young adult male liver (BXD29 and BXD15 winsori Metabolism
X366 13555 Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD31 winsorized from 243 to 200) [LDH/DNA rat Metabolism
X4516 13556 Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD15 deleted due to bad LDH control, BXD21 winsorized from 1 Metabolism
X3408 13557 Maximal hepatocyte cytotoxicity response 9 hr after treatment with lysis buffer, lactate dehydrogenase (LDH) release assay, young adult male liver [LDH] Metabolism
X903 13558 Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted d Metabolism
X4443 13559 Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted due to bad LDH c Metabolism
X3045 16925 Sphingomyelin (d16:1) _HFD for 20 weeks [nmol/mg] Metabolism
X2564 13560 Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay (relative fluorescent units), young adult male liver [RFU] Metabolism
X4845 13561 Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), ratio of ethanol-induced release to maximal (lysis) lactate dehydrogenase (LDH) release, young adult male liver (BXD15 deleted due to bad LDH control, BX Metabolism
X4238 14355 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data trimmed [ug hydroxyproline/g liver] Metabolism
X4512 14356 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] Metabolism
X1807 14357 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, trimmed [ug hydroxyproline/g liver] Metabolism
X2734 14358 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] Metabolism
X3033 14359 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data, trimmed [ug hydroxyproline/g liver] Metabolism
X3795 14360 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen data, trimmed [ug hydroxyproline/g liver] Metabolism
X2064 14361 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, trimmed [g] Metabolism
X2737 14362 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] Metabolism
X4829 14363 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] Metabolism
X4602 14364 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, Days 1 and 4), median liver to body weight ratio, data trimmed [g] Metabolism
X4045 14365 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] Metabolism
X4234 14366 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] Metabolism
X4132 14367 Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X3544 14368 Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X2496 14369 Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X2511 14370 Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X4759 14371 Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X4853 14372 Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X3684 14373 Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X3581 14374 Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X2026 14375 Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) activity, trimmed [U/l] Metabolism
X2057 14376 Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) activity, trimmed [U/l] Metabolism
X3807 14377 Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X4475 14378 Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] Metabolism
X4108 14379 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] Metabolism
X1211 14380 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] Metabolism
X3612 14381 Fibrosis susceptibility in males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] Metabolism
X3515 14382 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] Metabolism
X3916 14383 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] Metabolism
X4391 14384 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severety] Metabolism
X3649 14385 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X3298 14386 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X3968 14387 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X4801 14388 Fibrosis susceptibility in females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X4982 14389 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X4769 14390 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] Metabolism
X2237 14391 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory at Homburg), data trimmed [%] Metabolism
X2215 14392 Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, Homburg Laboratory), trimmed [%] Metabolism
X4161 14393 Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] Metabolism
X3696 14394 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] Metabolism
X4840 14395 Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] Metabolism
X4137 14396 fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] Metabolism
X335 14796 Acetaminophen (APAP) hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver [log2 LDH/DNA ratio treated/control] Metabolism
X4343 14975 Lung, morphology, Lung weight at 20 weeks in females and males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] Metabolism
X2696 15048 Food intake between 17 and 20 weeks in males on a high fat diet (45% energy from fat, Ssniff(R) diet S8074-E010, Germany) initiated at 4 weeks [g/day] Metabolism
X1969 15091 Saturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] Metabolism
X990 15092 Total fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] Metabolism
X530 15094 Ratio of lipid to protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] Metabolism
X532 15095 Ratio of total lipid to total protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [ratio] Metabolism
X4403 16181 Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 2 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] Metabolism
X3374 16182 Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 3 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] Metabolism
X2991 16183 Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 7 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] Metabolism
X4704 16229 Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males and females [% LDH supernatant of total LDH] Metabolism
X4162 16230 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in males and females [% LDH increase] Metabolism
X1510 16231 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta median in males and females [% LDH increase] Metabolism
X3215 16232 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males and females [% LDH increase] Metabolism
X4725 16233 Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males [% LDH supernatant of total LDH] Metabolism
X2575 16234 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol median in males [% LDH increase] Metabolism
X1635 16235 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in males [% LDH increase] Metabolism
X3662 16236 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males [% LDH increase] Metabolism
X3841 16237 Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment), median in females [% LDH supernatant of total LDH] Metabolism
X4149 16238 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in females [% LDH increase] Metabolism
X2297 16239 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in females [% LDH increase] Metabolism
X444 16240 Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol median in females [% LDH increase vs. untreated cells] Metabolism
X96 16604 Induction of CYP1B1 mRNA after treatment with beta-Naphthoflavone (BNF, 15 uM for 24 h), measured by rtPCR in cryorederived primary hepatocytes (Varigenix CRL Panel, three technical replicates/strain/treatment) [fold-incre Metabolism
X4449 10108 Striatum cholinergic neurons in section 17 [n/section] Nervous system
X635 16605 Basal CYP1B1 mRNA expression measured by rtPCR in cryorederived primary hepatocytes in DMSO (Varigenix CRL Panel, three technical replicates/strain/treatment, higher numbers = lower endogenous expression, the Cyp1b1 gene i Metabolism
X3118 16874 Total sphingomyelin_CDHFD [nmol/ml] Metabolism
X1961 16875 Total sphingomyelin_HFD for 20 weeks [nmol/ml] Metabolism
X2089 16876 Total sphingomyelin_CD [nmol/ml] Metabolism
X4647 16905 Sphingomyelin (d16:1) _CD [nmol/mg] Metabolism
X1604 16906 Sphingomyelin (d18:2) _CD [nmol/mg] Metabolism
X4834 16907 Sphingomyelin (d16:0) _CD [nmol/mg] Metabolism
X1463 16908 Sphingomyelin (d18:1) _CD [nmol/mg] Metabolism
X1439 16909 Total sphingomyelin _CD [nmol/mg] Metabolism
X4930 16910 Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CD [pmol/mg] Metabolism
X1352 16911 Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CD [AU/mg] Metabolism
X1755 16912 N-glycolyl GM2 (ganglioside) _CD [nmol/mg] Metabolism
X1599 16913 Gluco(galacto)sylceramide _CD [nmol/mg] Metabolism
X1824 16914 Ceramide (d18:1) _CD [nmol/mg] Metabolism
X3658 16915 Acid beta-glucosidase activity _CD [nmol/(hour*mg)] Metabolism
X4903 16916 Hexosaminidase activity _CD [nmol/(hour*mg)] Metabolism
X4062 16917 Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver _CD Metabolism
X4350 16918 Ratio of Total sphingomyelin/Ceramide levels in liver _CD Metabolism
X836 16919 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CD Metabolism
X2768 16920 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CD Metabolism
X2628 16921 Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CD Metabolism
X1018 16922 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CD Metabolism
X5001 16923 Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CD Metabolism
X1894 10363 Hippocampus mossy fiber pathway volume, CA4 (dentate gyrus) component [volume units] Morphology
X2243 16926 Sphingomyelin (d18:2) _HFD for 20 weeks [nmol/mg] Metabolism
X1986 16927 Sphingomyelin (d16:0) _HFD for 20 weeks [nmol/mg] Metabolism
X4384 16928 Sphingomyelin (d18:1) _HFD for 20 weeks [nmol/mg] Metabolism
X4050 16929 Total sphingomyelin _HFD for 20 weeks [nmol/mg] Metabolism
X2872 16930 Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [pmol/mg] Metabolism
X3709 16931 Globotriaosylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [AU/mg] Metabolism
X3328 16932 N-glycolyl GM2 (ganglioside) _HFD for 20 weeks [nmol/mg] Metabolism
X1227 16933 Gluco(galacto)sylceramide _HFD for 20 weeks [nmol/mg] Metabolism
X1826 16934 Ceramide (d18:1) _HFD for 20 weeks [nmol/mg] Metabolism
X3982 16935 Acid beta-glucosidase activity _HFD for 20 weeks [nmol/(min*mg)] Metabolism
X2796 16936 Hexosaminidase activity _HFD for 20 weeks [nmol/(min*mg)] Metabolism
X2569 16937 Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver after overnight fasting in males at 29 weeks of age_HFD for 20 weeks Metabolism
X2054 16938 Ratio of Total sphingomyelin/Ceramide levels in liver _HFD for 20 weeks Metabolism
X2079 16939 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _HFD for 20 weeks Metabolism
X2965 16940 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks Metabolism
X2770 16941 Ratio of Globotriaosylsphingosine/Ceramide levels in liver _HFD for 20 weeks Metabolism
X3646 16942 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks Metabolism
X2760 16943 Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks Metabolism
X1842 16944 Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _HFD for 20 weeks Metabolism
X2570 16945 Sphingomyelin (d16:1) _CDHFD [nmol/mg] Metabolism
X2631 16946 Sphingomyelin (d18:2) _CDHFD [nmol/mg] Metabolism
X4104 16947 Sphingomyelin (d16:0) _CDHFD [nmol/mg] Metabolism
X1621 16948 Sphingomyelin (d18:1) _CDHFD [nmol/mg] Metabolism
X1725 16949 Total sphingomyelin _CDHFD [nmol/mg] Metabolism
X1360 16950 Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CDHFD [pmol/mg] Metabolism
X1145 16951 Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CDHFD [AU/mg] Metabolism
X702 16952 N-glycolyl GM2 (ganglioside) _CDHFD [nmol/mg] Metabolism
X3201 16953 Gluco(galacto)sylceramide _CDHFD [nmol/mg] Metabolism
X2571 16954 Ceramide (d18:1) _CDHFD [nmol/mg] Metabolism
X932 16955 Acid beta-glucosidase activity _CDHFD [nmol/(min*mg)] Metabolism
X4290 16956 Hexosaminidase activity _CDHFD [nmol/(min*mg)] Metabolism
X2963 16957 Ratio of Gluco(galacto)sylceramide/Ceramide levels in liverafter overnight fasting in males at 29 weeks of age_CDHFD [units] Metabolism
X2792 16958 Ratio of Total sphingomyelin/Ceramide levels in liver _CDHFD [units] Metabolism
X166 16959 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CDHFD [units] Metabolism
X1648 16960 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CDHFD [units] Metabolism
X607 16961 Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CDHFD [units] Metabolism
X826 16962 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] Metabolism
X2793 16963 Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] Metabolism
X2036 16964 Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CDHFD [units] Metabolism
X5074 17020 Diabetes model, response to alloxan (80 mg/kg iv to induce diabetes by killing pancretic beta cells), kidney weight 7 days after treatment as a percentage of body weight in adult males and females without statistical adjust Metabolism
X975 17023 Diabetes model, alloxan response (80 mg/kg iv to induce diabetes by killing pancretic beta cells), eye weight 7 days after treatment as a percentage of body weight in adult males and females without statistical Metabolism
X4353 17466 Life span, longevity of females (mean age) at UTHSC, Memphis TN, on standard low fat diet (Harlan Teklad 2018 chow diet, 18.6% protein, 6.2% fat, 3.1 kcal/g of which 18% are from fat), 12 hr light cycle in polypropylene cages (145 sq-in with up to Metabolism
X1318 17468 Life span, longevity of females (mean age) at UTHSC, Memphis TN, on high fat diet (Harlan Teklad 06414, 18.4% protein, 60.3% calories from fat, 5.1 kcal/g), 12 hr light cycle in polypropylene cages (145 sq-in with up to 10 animals/cage, Harlan Tekl Metabolism
X3229 12589 Hippocampus mossy fiber pathway volume, suprapyramidal (SMF) [mm^3] Morphology
X4321 17469 Life span, longevity difference of females at UTHSC on either a normal low fat chow diet or a high fat diet (60% calories from fat), 12 hr light cycle (only computed if more than 4 cases per diet) [days] Metabolism
X173 17475 Life span, longevity of females (median age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to Metabolism
X373 17548 Lrp6 mRNA expression in liver after carbon tetrachloride treatment, first principal component generated using SNP-free exon probe sets (exons 14, 17 and 18) and SUH_Liv_RMAEx_0611 data [relative residual concentration] Metabolism
X1332 17549 Lrp6 mRNA expression in untreated rederived hepatocytes, first principal component eigengene (loads heavily on almost all central exons, from exon 4 to exon 21, 40% of variance) with correct polarity generated using 18 SNP-free exo Metabolism
X4395 17550 Lrp6 mRNA expression in untreated rederived hepatocytes, second principal component eigengene (loads mainly on most proximal and most distal exons, exon 1, 22 and 23, 17% of total variance) with correct polarity generated using 18 Metabolism
X2656 17551 Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [ratio of ug/mg] Metabolism
X3740 17552 Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine log ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [log ratio of ug/mg] Metabolism
X4783 17611 Respiratory exchange ratio (RER) light phase (day) _CD, males [ratio] Metabolism
X5014 17612 Respiratory exchange ratio (RER) light phase (day) _HFD, males [ratio] Metabolism
X4962 17613 Respiratory exchange ratio (RER) dark phase (night) _CD, males [ratio] Metabolism
X4992 17614 Respiratory exchange ratio (RER) dark phase (night) _HFD, males [ratio] Metabolism
X4945 17615 Respiratory exchange ratio (RER) over 24 hours _CD, males [ratio] Metabolism
X5003 17616 Respiratory exchange ratio (RER) over 24 hours _HFD, males [ratio] Metabolism
X4320 17617 VO2 light phase (day) average _CD, males [mL/kg/h] Metabolism
X1563 17618 VO2 light phase (day) average _HFD, males [mL/kg/h] Metabolism
X4318 17619 VO2 dark phase (night) average _CD, males [mL/kg/h] Metabolism
X1443 17620 VO2 dark phase (night) average _HFD, males [mL/kg/h] Metabolism
X4468 17621 VO2 over 24 hours _CD, males [mL/kg/h] Metabolism
X1558 17622 VO2 over 24 hours _HFD, males [mL/kg/h] Metabolism
X3623 17623 VCO2 light phase (day) average _CD, males [mL/kg/h] Metabolism
X1672 17624 VCO2 light phase (day) average _HFD, males [mL/kg/h] Metabolism
X3897 17625 VCO2 dark phase (night) average _CD, males [mL/kg/h] Metabolism
X1321 17626 VCO2 dark phase (night) average _HFD, males [mL/kg/h] Metabolism
X4022 17627 VCO2 over 24 hours _CD, males [mL/kg/h] Metabolism
X1470 17628 VCO2 over 24 hours _HFD, males [mL/kg/h] Metabolism
X1365 17633 Food intake in 24 h _CD, males [g] Metabolism
X3078 17634 Food intake in 24 h _HFD, males [g] Metabolism
X1364 17635 Food intake in 24 h _CD, males [kCal] Metabolism
X3079 17636 Food intake in 24 h _HFD, males [kCal] Metabolism
X4487 17637 Water intake in 24 h _CD, males [mL] Metabolism
X2987 17638 Water intake in 24 h _HFD, males [mL] Metabolism
X1148 17639 VO2 light phase (day) average, lean mass corrected _CD, males [mL/kg/h] Metabolism
X2207 17640 VO2 light phase (day) average, lean mass corrected _HFD, males [mL/kg/h] Metabolism
X1411 17641 VO2 dark phase (night) average, lean mass corrected _CD, males [mL/kg/h] Metabolism
X821 17642 VO2 dark phase (night) average, lean mass corrected _HFD, males [mL/kg/h] Metabolism
X2958 17643 Glycemia after overnight fast_CD, males [mg/mL] Metabolism
X1983 17644 Glycemia after overnight fast_HFD, males [mg/mL] Metabolism
X2585 17645 OGTT_ 15min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X1718 17646 OGTT_ 15min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X1271 17647 OGTT_ 30 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X2893 17648 OGTT_ 30 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X931 17649 OGTT_ 45min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X3597 17650 OGTT_ 45min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X858 17651 OGTT_ 60 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X3220 17652 OGTT_ 60 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X1419 17653 OGTT_ 90 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X599 17654 OGTT_ 90 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X3164 17655 OGTT_ 120 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X3312 17656 OGTT_ 120 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X4608 17657 OGTT_ 150 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X4588 17658 OGTT_ 150 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X4791 17659 OGTT_ 180 min, at 17 weeks of age_CD, males [mg/mL] Metabolism
X4046 17660 OGTT_ 180 min, at 17 weeks of age_HFD, males [mg/mL] Metabolism
X1259 17661 OGTT_ overall_CD, males [AUC] Metabolism
X2751 17662 OGTT_ overall_HFD, males [AUC] Metabolism
X2075 17663 Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [AUC] Metabolism
X1862 17664 Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [AUC] Metabolism
X3518 17665 Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_CD, males [ug/mL] Metabolism
X4609 17666 Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_HFD, males [ug/mL] Metabolism
X2203 17667 Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_CD, males [ug/mL] Metabolism
X1106 17668 Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_HFD, males [ug/mL] Metabolism
X837 17669 Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_CD, males [ug/mL] Metabolism
X1536 17670 Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_HFD, males [ug/mL] Metabolism
X1971 17671 Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males [ratio] Metabolism
X5043 17672 Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males [ratio] Metabolism
X5011 17673 Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] Metabolism
X1773 17674 Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] Metabolism
X4437 17675 Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] Metabolism
X2104 17676 Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] Metabolism
X4182 17677 Glucose * insulin in plasma after overnight fast, at 17 weeks of age_CD, males [(ug*mg)/(mL*mL)] Metabolism
X4164 17678 Glucose * insulin in plasma after overnight fast, at 17 weeks of age_HFD, males [(ug*mg)/(mL*mL)] Metabolism
X3432 17679 McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males. This phenotype is part of the EPFL LISP3 Study. Metabolism
X4574 17680 McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males. This phenotype is part of the EPFL LISP3 Study. Metabolism
X3424 17681 HOMA-IR after overnight fast, at 17 weeks of age_CD, males [index] Metabolism
X3676 17682 HOMA-IR after overnight fast, at 17 weeks of age_HFD, males [index] Metabolism
X4656 17683 HOMA-B after overnight fast, at 17 weeks of age_CD, males [index] Metabolism
X4225 17684 HOMA-B after overnight fast, at 17 weeks of age_HFD, males [index] Metabolism
X374 17685 Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] Metabolism
X2426 17686 Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] Metabolism
X1787 17687 Systolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] Metabolism
X3593 17688 Systolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] Metabolism
X1833 17689 Heart rate measured using a tail cuff system at 19 weeks of age_CD, males [bpm] Metabolism
X1384 17690 Heart rate measured using a tail cuff system at 19 weeks of age_HFD, males [bpm] Metabolism
X860 17691 Body temperature, basal, at 21 weeks of age_CD, males [Celsius] Metabolism
X2428 17692 Body temperature, basal, at 21 weeks of age_HFD, males [deg C] Metabolism
X1109 17693 Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X4785 17694 Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X1299 17695 Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X3688 17696 Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X2567 17697 Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X2413 17698 Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X3310 17699 Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X1458 17700 Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X865 17701 Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X648 17702 Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X2874 17703 Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] Metabolism
X756 17704 Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] Metabolism
X1595 17705 Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] Metabolism
X1881 17706 Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] Metabolism
X3677 17707 Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] Metabolism
X1749 17708 Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] Metabolism
X4179 17709 Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_CD, males [%] Metabolism
X1665 17710 Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_HFD, males [%] Metabolism
X3209 17711 Body temperature, basal, diet ratio, at 21 weeks of age_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] Metabolism
X1973 17712 Body temperature, after 6 hours in 4 deg C chamber at 21 weeks of age, diet ratio_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] Metabolism
X4197 17725 Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [g] Metabolism
X732 17726 Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [g] Metabolism
X3690 17727 Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [kCal] Metabolism
X907 17728 Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [kCal] Metabolism
X275 17729 Food intake/body weight g, standard housing cage at 23 weeks of age_CD, males [g/g] Metabolism
X4886 17730 Food intake/body weight g, standard housing cage at 23 weeks of age_HFD, males [g/g] Metabolism
X1208 17739 VO2 basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] Metabolism
X2052 17740 VO2 basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] Metabolism
X595 17741 VO2 max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] Metabolism
X2141 17742 VO2 max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] Metabolism
X4461 17743 Respiratory exchange ratio (RER) basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] Metabolism
X4957 17744 Respiratory exchange ratio (RER) basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] Metabolism
X3698 10364 Hippocampus mossy fiber pathway volume, suprapyramidal component (SPMF) [units] Morphology
X5085 17745 Respiratory exchange ratio (RER) max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] Metabolism
X2489 17746 Respiratory exchange ratio (RER) max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] Metabolism
X2262 17747 VO2 basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] Metabolism
X2252 17748 VO2 basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] Metabolism
X3825 17749 VO2 max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] Metabolism
X1730 17750 VO2 max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] Metabolism
X4465 17751 Respiratory exchange ratio (RER) basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] Metabolism
X2755 17752 Respiratory exchange ratio (RER) basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] Metabolism
X1886 17753 Respiratory exchange ratio (RER) max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] Metabolism
X883 17754 Respiratory exchange ratio (RER) max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] Metabolism
X3084 17755 VO2 basal improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] Metabolism
X4312 17756 VO2 basal improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] Metabolism
X1196 17757 VO2 max improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] Metabolism
X3624 17758 VO2 max improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] Metabolism
X4122 17759 Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [ratio] Metabolism
X3627 17760 Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [ratio] Metabolism
X5047 18404 Urinary albumin/creatinin ratio (ACR microgram/milligram) in following longterm diabetes induced by streptozotocin (STZ) treatment [ug/mg] Metabolism
X3098 18430 Ejection fraction by echocardiography of 17-week old females and males [%] Metabolism
X1830 18431 Shortening fraction by echocardiography of 17-week old females and males [%] Metabolism
X4222 18432 Ejection fraction by echocardiography of 17-week old paired females and males [%] Metabolism
X1390 18433 Shortening fraction by echocardiography of 17-week old paired females and males [%] Metabolism
X2379 16641 C12-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X2478 18435 Life span, longevity of females at UTHSC on high fat diet (Harlan Teklad 06414, 60.3% calories from fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=382) [days] Metabolism
X4730 18441 Life span, longevity of females at UTHSC on standard chow diet (Harlan Teklad 2018 chow diet, 6.2% fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=357) [days] Metabolism
X4007 14308 Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum] Metabolites
X1641 14337 Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum, log] Metabolites
X2658 16622 Alanine levels_CDHFD [nmol/ml] Metabolites
X4328 16623 Alanine levels_HFD for 20 weeks [nmol/ml] Metabolites
X2006 16624 Alanine levels_CD [nmol/ml] Metabolites
X170 16625 Alpha-aminoadipate levels_CDHFD [nmol/ml] Metabolites
X319 16626 Alpha-aminoadipate levels_HFD for 20 weeks [nmol/ml] Metabolites
X164 16627 Alpha-aminoadipate levels_CD [nmol/ml] Metabolites
X4356 16628 Asparagine levels_CDHFD [nmol/ml] Metabolites
X3179 16629 Asparagine levels_HFD for 20 weeks [nmol/ml] Metabolites
X1879 16630 Asparagine levels_CD [nmol/ml] Metabolites
X1195 16631 C0-carnitine_CDHFD [nmol/ml] Metabolites
X3715 16632 C0-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X1578 16633 C0-carnitine_CD [nmol/ml] Metabolites
X3670 16634 C10-carnitine_CDHFD [nmol/ml] Metabolites
X2692 16635 C10-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4669 16636 C10-carnitine_CD [nmol/ml] Metabolites
X1262 16637 C12:1-carnitine_CDHFD [nmol/ml] Metabolites
X3378 16638 C12:1-carnitine_CD [nmol/ml] Metabolites
X2395 16639 C12:1-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3767 16640 C12-carnitine_CDHFD [nmol/ml] Metabolites
X4274 16642 C12-carnitine_CD [nmol/ml] Metabolites
X3074 16643 C12-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X2113 16644 C12-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4842 16645 C12-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4605 16646 C14:1-carnitine_CDHFD [nmol/ml] Metabolites
X3339 16647 C14:1-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3372 16648 C14:1-carnitine_CD [nmol/ml] Metabolites
X3508 16649 C14:1-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X3959 16650 C14:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X2873 16651 C14:1-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4370 16652 C14:2-carnitine_CDHFD [nmol/ml] Metabolites
X3181 16653 C14:2-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4205 16654 C14:2-carnitine_CD [nmol/ml] Metabolites
X4750 16655 C14-carnitine_CDHFD [nmol/ml] Metabolites
X2740 16656 C14-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4817 16657 C14-carnitine_CD [nmol/ml] Metabolites
X4670 16658 C16:1-carnitine_CDHFD [nmol/ml] Metabolites
X3297 16660 C16:1-carnitine_CD [nmol/ml] Metabolites
X1453 16661 C16:1-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X1199 16662 C16:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3038 16663 C16:1-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4865 16664 C16:2-carnitine_CDHFD [nmol/ml] Metabolites
X4561 16665 C16:2-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4813 16666 C16:2-carnitine_CD [nmol/ml] Metabolites
X4503 12590 Hippocampus mossy fiber pathway volume, hilus [mm^3] Morphology
X4488 16667 C16-carnitine_CDHFD [nmol/ml] Metabolites
X1924 16668 C16-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4906 16669 C16-carnitine_CD [nmol/ml] Metabolites
X484 16670 C16-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3944 16671 C16-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X4302 16672 C16-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4056 16673 C18:1-carnitine_CDHFD [nmol/ml] Metabolites
X2072 16674 C18:1-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3781 16675 C18:1-carnitine_CD [nmol/ml] Metabolites
X1544 16676 C18:1-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X3664 16677 C18:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4309 16678 C18:1-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4195 16679 C18:2-carnitine_CDHFD [nmol/ml] Metabolites
X3675 16680 C18:2-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3761 16681 C18:2-carnitine_CD [nmol/ml] Metabolites
X2094 16682 C18-carnitine_CDHFD [nmol/ml] Metabolites
X2121 16683 C18-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4955 16684 C18-carnitine_CD [nmol/ml] Metabolites
X4764 16685 C2-carnitine-acetylcarnitine_CDHFD [nmol/ml] Metabolites
X4146 16686 C2-carnitine-acetylcarnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4550 16687 C2-carnitine-acetylcarnitine_CD [nmol/ml] Metabolites
X3271 16688 C4-hydroxy-carnitine_CDHFD [nmol/ml] Metabolites
X4720 16689 C4-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X2860 16690 C4-hydroxy-carnitine_CD [nmol/ml] Metabolites
X4987 12906 Body weight of 17-week old males [g] Morphology
X286 16691 C5 dicarboxylylcarnitine_CDHFD [nmol/ml] Metabolites
X2827 16692 C5 dicarboxylylcarnitine_HFD for 20 weeks [nmol/ml] Metabolites
X1914 16693 C5 dicarboxylylcarnitine_CD [nmol/ml] Metabolites
X2780 16694 C6-carnitine_CDHFD [nmol/ml] Metabolites
X4643 16695 C6-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X2221 16696 C6-carnitine_CD [nmol/ml] Metabolites
X4261 16697 C8-carnitine_CDHFD [nmol/ml] Metabolites
X1482 16698 C8-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X4843 16699 C8-carnitine_CD [nmol/ml] Metabolites
X2733 16700 Ceramide (d18:1)_CDHFD [nmol/ml] Metabolites
X2703 16701 Ceramide (d18:1)_HFD for 20 weeks [nmol/ml] Metabolites
X322 16702 Ceramide (d18:1)_CD [nmol/ml] Metabolites
X3718 16703 Citrulline levels_CDHFD [nmol/ml] Metabolites
X2801 16704 Citrulline levels_HFD for 20 weeks [nmol/ml] Metabolites
X4027 16705 Citrulline levels_CD [nmol/ml] Metabolites
X758 16706 Globotriaosylsphingosine levels (without sphingomyelinase)_CDHFD [nmol/ml] Metabolites
X855 16707 Globotriaosylsphingosine levels (without sphingomyelinase)_HFD for 20 weeks [nmol/ml Metabolites
X2802 16708 Globotriaosylsphingosine levels (without sphingomyelinase)_CD [nmol/ml] Metabolites
X1124 16709 Gluco(galacto)sylceramide_CDHFD [nmol/ml] Metabolites
X3926 16710 Gluco(galacto)sylceramide_HFD for 20 weeks [nmol/ml] Metabolites
X2398 16711 Gluco(galacto)sylceramide_CD [nmol/ml] Metabolites
X4408 16712 Glutamate levels_CDHFD [nmol/ml] Metabolites
X1339 16713 Glutamate levels_HFD for 20 weeks [nmol/ml] Metabolites
X3163 16714 Glutamate levels_CD [nmol/ml] Metabolites
X3475 16715 Glutamine levels_CDHFD [nmol/ml] Metabolites
X2833 16716 Glutamine levels_HFD for 20 weeks [nmol/ml] Metabolites
X3674 16717 Glutamine levels_CD [nmol/ml] Metabolites
X241 16718 Glycine levels_CDHFD [nmol/ml] Metabolites
X308 16719 Glycine levels_HFD for 20 weeks [nmol/ml] Metabolites
X540 16720 Glycine levels_CD [nmol/ml] Metabolites
X3364 16721 Isoleucine levels_CDHFD [nmol/ml] Metabolites
X4971 16722 Isoleucine levels_HFD for 20 weeks [nmol/ml] Metabolites
X1269 16723 Isoleucine levels_CD [nmol/ml] Metabolites
X2294 16724 Kynurenine levels_CDHFD [nmol/ml] Metabolites
X2693 16725 Kynurenine levels_HFD for 20 weeks [nmol/ml] Metabolites
X1568 16726 Kynurenine levels_CD [nmol/ml] Metabolites
X2555 16727 Leucine levels_CDHFD [nmol/ml] Metabolites
X2423 16728 Leucine levels_HFD for 20 weeks [nmol/ml] Metabolites
X2602 16729 Leucine levels_CD [nmol/ml] Metabolites
X3191 16730 Lysine levels_CDHFD [nmol/ml] Metabolites
X4810 16731 Lysine levels_HFD for 20 weeks [nmol/ml] Metabolites
X1794 16732 Lysine levels_CD [nmol/ml] Metabolites
X2981 16733 Methionine levels_CDHFD [nmol/ml] Metabolites
X4784 16734 Methionine levels_HFD for 20 weeks [nmol/ml] Metabolites
X1113 16735 Methionine levels_CD [nmol/ml] Metabolites
X2892 16736 Natural logarithm of Arginine levels_CDHFD [nmol/ml] Metabolites
X2151 16737 Arginine levels (LogN)_HFD for 20 weeks [logN nmol/ml] Metabolites
X4438 16738 Natural logarithm of Arginine levels_CD [nmol/ml] Metabolites
X516 16831 Ratio of ornithine/citrulline_CD Metabolites
X1112 16739 Natural logarithm of Aspartate levels_CDHFD [nmol/ml] Metabolites
X1758 16740 Natural logarithm of Aspartate levels_HFD for 20 weeks [nmol/ml] Metabolites
X2349 16741 Natural logarithm of Aspartate levels_CD [nmol/ml] Metabolites
X104 16742 Natural logarithm of C3 dicarboxylylcarnitine_CDHFD [nmol/ml] Metabolites
X103 16743 C3 dicarboxylylcarnitine_HFD for 20 weeks [logN nmol/ml] Metabolites
X119 16744 Natural logarithm of C3 dicarboxylylcarnitine_CD [nmol/ml] Metabolites
X1247 16745 Natural logarithm of C3-carnitine_propionylcarnitine_CDHFD [nmol/ml] Metabolites
X774 16746 Natural logarithm of C3-carnitine_propionylcarnitine_HFD for 20 weeks [nmol/ Metabolites
X1542 16747 Natural logarithm of C3-carnitine_propionylcarnitine_CD [nmol/ml] Metabolites
X3560 16748 Natural logarithm of C4-carnitine_CDHFD [nmol/ml] Metabolites
X4100 16749 Natural logarithm of C4-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X3061 16750 Natural logarithm of C4-carnitine_CD [nmol/ml] Metabolites
X675 16751 Natural logarithm of C5-carnitine_CDHFD [nmol/ml] Metabolites
X3281 16752 Natural logarithm of C5-carnitine_HFD for 20 weeks [nmol/ml] Metabolites
X346 16753 Natural logarithm of C5-carnitine_CD [nmol/ml] Metabolites
X590 16754 Natural logarithm of Fasting glucose_CDHFD [mg/ml] Metabolites
X1714 16755 Natural logarithm of Fasting glucose_HFD for 20 weeks [mg/ml] Metabolites
X1589 16756 Natural logarithm of Fasting glucose_CD [mg/ml] Metabolites
X4641 16757 Natural logarithm of N-glycolyl GM2 (ganglioside)_CDHFD [nmol/ml] Metabolites
X3169 16758 Natural logarithm of N-glycolyl GM2 (ganglioside)_HFD for 20 weeks [nmol/ml] Metabolites
X3466 16759 Natural logarithm of N-glycolyl GM2 (ganglioside)_CD [nmol/ml] Metabolites
X304 16760 Natural logarithm of Phenylalanine levels_CDHFD [nmol/ml] Metabolites
X583 16761 Natural logarithm of Phenylalanine levels_HFD for 20 weeks [nmol/ml] Metabolites
X637 16762 Natural logarithm of Phenylalanine levels_CD [nmol/ml] Metabolites
X3701 16763 Natural logarithm of Proline levels_CDHFD [nmol/ml] Metabolites
X4324 16764 Natural logarithm of Proline levels_HFD for 20 weeks [nmol/ml] Metabolites
X3882 16765 Natural logarithm of Proline levels_CD [nmol/ml] Metabolites
X252 16766 Ornithine levels_CDHFD [nmol/ml] Metabolites
X1691 16767 Ornithine levels_HFD for 20 weeks [nmol/ml] Metabolites
X178 16768 Ornithine levels_CD [nmol/ml] Metabolites
X265 16769 Alpha-aminoadipate to lysine ratio_CDHFD [ratio] Metabolites
X700 16770 Alpha-aminoadipate to lysine ratio_HFD for 20 weeks [ratio] Metabolites
X222 16771 Alpha-aminoadipate to lysine ratio_CD [ratio] Metabolites
X728 16772 Ratio of total branched-chain amino acid/Alanine_CDHFD [units] Metabolites
X1609 16773 Ratio of total branched-chain amino acid/Alanine_HFD for 20 weeks Metabolites
X1328 16774 Ratio of total branched-chain amino acid/Alanine_CD Metabolites
X1598 16775 Ratio of total branched-chain amino acid/C3-carnitine_CDHFD [units] Metabolites
X3121 16776 Ratio of total branched-chain amino acid/C3-carnitine_HFD for 20 weeks Metabolites
X2949 16777 Ratio of total branched-chain amino acid/C3-carnitine_CD Metabolites
X3051 16778 Ratio of total branched-chain amino acid/Glutamine_CDHFD [units] Metabolites
X2128 16779 Ratio of total branched-chain amino acid/Glutamine_HFD for 20 weeks Metabolites
X4823 16780 Ratio of total branched-chain amino acid/Glutamine_CD Metabolites
X2315 16781 Ratio of total branched-chain amino acid/total amino acid_HFD for 20 weeks Metabolites
X1388 16782 Ratio of total branched-chain amino acid/total amino acid_CDHFD [units] Metabolites
X4005 16832 Ratio of phenylalanine/tyrosine_CDHFD [units] Metabolites
X1224 16783 Ratio of total branched-chain amino acid/total amino acid_CD Metabolites
X1707 16784 Ratio of C0-carnitine/C2-carnitine_CDHFD [units] Metabolites
X4163 16785 Ratio of C0-carnitine/C2-carnitine_HFD for 20 weeks Metabolites
X3661 16786 Ratio of C0-carnitine/C2-carnitine_CD Metabolites
X2329 16787 Ratio of C14:1-carnitine/C14-carnitine_CDHFD [units] Metabolites
X2017 16788 Ratio of C14:1-carnitine/C14-carnitine_HFD for 20 weeks Metabolites
X2476 16789 Ratio of C14:1-carnitine/C14-carnitine_CD Metabolites
X3286 16790 Ratio of C14:1-carnitine/C2-carnitine_CDHFD [units] Metabolites
X4289 16791 Ratio of C14:1-carnitine/C2-carnitine_HFD for 20 weeks Metabolites
X3320 16792 Ratio of C14:1-carnitine/C2-carnitine_CD Metabolites
X1565 16793 Ratio of C14:2-carnitine/C14:1-carnitine_CDHFD [units] Metabolites
X3422 16795 Ratio of C14:2-carnitine/C14:1-carnitine_CD Metabolites
X1294 16796 Ratio of C16:1-carnitine/C16-carnitine_CDHFD [units] Metabolites
X2424 16797 Ratio of C16:1-carnitine/C16-carnitine_HFD for 20 weeks Metabolites
X1397 16798 Ratio of C16:1-carnitine/C16-carnitine_CD Metabolites
X1825 16799 Ratio of C16:2-carnitine/C16:1-carnitine_CDHFD [units] Metabolites
X3734 16800 Ratio of C16:2-carnitine/C16:1-carnitine_HFD for 20 weeks Metabolites
X2306 16801 Ratio of C16:2-carnitine/C16:1-carnitine_CD Metabolites
X3042 16802 Ratio of C18:1-carnitine/C18-carnitine_CDHFD [units] Metabolites
X4595 16803 Ratio of C18:1-carnitine/C18-carnitine_HFD for 20 weeks Metabolites
X4638 16804 Ratio of C18:1-carnitine/C18-carnitine_CD Metabolites
X1164 16805 Ratio of C18:2-carnitine/C18:1-carnitine_CDHFD [units] Metabolites
X771 16806 Ratio of C18:2-carnitine/C18:1-carnitine_HFD for 20 weeks Metabolites
X629 16807 Ratio of C18:2-carnitine/C18:1-carnitine_CD Metabolites
X4509 16808 Ratio of Gluco(galacto)sylceramide/Ceramide_CDHFD [units] Metabolites
X761 16809 Ratio of Gluco(galacto)sylceramide/Ceramide_HFD for 20 weeks Metabolites
X2464 16810 Ratio of Gluco(galacto)sylceramide/Ceramide_CD Metabolites
X1395 16811 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CDHFD [units] Metabolites
X1297 16812 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_HFD for 20 weeks Metabolites
X852 16813 Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CD Metabolites
X3394 16814 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CDHFD [units] Metabolites
X4070 16815 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_HFD for 20 weeks Metabolites
X3810 16816 Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CD Metabolites
X3421 16817 Ratio of Isoleucine/C3-carnitine_CDHFD [units] Metabolites
X1705 16818 Ratio of Isoleucine/C3-carnitine_HFD for 20 weeks Metabolites
X2797 16819 Ratio of Isoleucine/C3-carnitine_CD Metabolites
X1219 16820 Ratio of Kynurenine/Tryptophan_CDHFD [units] Metabolites
X1420 16821 Ratio of Kynurenine/Tryptophan_HFD for 20 weeks Metabolites
X1004 16822 Ratio of Kynurenine/Tryptophan_CD Metabolites
X2463 16823 Ratio of Globotriaosylsphingosine/Ceramide_CDHFD [units] Metabolites
X2565 16824 Ratio of Globotriaosylsphingosine/Ceramide_HFD for 20 weeks Metabolites
X2282 16825 Ratio of Globotriaosylsphingosine/Ceramide_CD Metabolites
X2817 16826 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CDHFD [units] Metabolites
X1456 16827 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_HFD for 20 weeks Metabolites
X3681 16828 Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CD Metabolites
X533 16829 Ratio of ornithine/citrulline_CDHFD [units] Metabolites
X1974 16830 Ratio of ornithine/citrulline_HFD for 20 weeks Metabolites
X4818 16833 Ratio of phenylalanine/tyrosine_HFD for 20 weeks Metabolites
X4053 16834 Ratio of phenylalanine/tyrosine_CD Metabolites
X2977 16835 Ratio of total long chain acylcarnitine/C0-carnitine_CDHFD [units] Metabolites
X3683 16836 Ratio of total long chain acylcarnitine/C0-carnitine_HFD for 20 weeks Metabolites
X4998 16837 Ratio of total long chain acylcarnitine/C0-carnitine_CD Metabolites
X2219 16838 Ratio of total long chain acylcarnitine/C2-carnitine_CDHFD [units] Metabolites
X2296 16839 Ratio of total long chain acylcarnitine/C2-carnitine_HFD for 20 weeks Metabolites
X2924 16840 Ratio of total long chain acylcarnitine/C2-carnitine_CD Metabolites
X1416 16841 Ratio of total sphingomyelin/ceramide_CDHFD [units] Metabolites
X1848 16842 Ratio of total sphingomyelin/ceramide_HFD for 20 weeks Metabolites
X1698 16843 Ratio of total sphingomyelin/ceramide_CD Metabolites
X1445 16844 Ratio of Valine/C3-carnitine_CDHFD [units] Metabolites
X3319 16845 Ratio of Valine/C3-carnitine_HFD for 20 weeks Metabolites
X1907 16846 Ratio of Valine/C3-carnitine_CD Metabolites
X3521 16847 Serine levels_CDHFD [nmol/ml] Metabolites
X3691 16848 Serine levels_HFD for 20 weeks [nmol/ml] Metabolites
X4058 16849 Serine levels_CD [nmol/ml] Metabolites
X4786 16850 Sphingomyelin (d16:0)_CDHFD [nmol/ml] Metabolites
X3454 16851 Sphingomyelin (d16:0)_HFD for 20 weeks [nmol/ml] Metabolites
X4474 16852 Sphingomyelin (d16:0)_CD [nmol/ml] Metabolites
X2710 16853 Sphingomyelin (d16:1)_CDHFD [nmol/ml] Metabolites
X2456 16854 Sphingomyelin (d16:1)_HFD for 20 weeks [nmol/ml] Metabolites
X4237 16855 Sphingomyelin (d16:1)_CD [nmol/ml] Metabolites
X2853 16856 Sphingomyelin (d18:1)_CDHFD [nmol/ml] Metabolites
X1557 16857 Sphingomyelin (d18:1)_HFD for 20 weeks [nmol/ml] Metabolites
X1673 16858 Sphingomyelin (d18:1)_CD [nmol/ml] Metabolites
X2812 16859 Sphingomyelin (d18:2)_CDHFD [nmol/ml] Metabolites
X2085 16860 Sphingomyelin (d18:2)_HFD for 20 weeks [nmol/ml] Metabolites
X4479 16861 Sphingomyelin (d18:2)_CD [nmol/ml] Metabolites
X2112 16862 Spingosine-1-phosphate levels_CDHFD [pmol/ml] Metabolites
X3954 16863 Spingosine-1-phosphate levels_HFD for 20 weeks [pmol/ml] Metabolites
X300 16864 Spingosine-1-phosphate levels_CD [pmol/ml] Metabolites
X2701 16865 Total amino acid levels_CDHFD [nmol/ml] Metabolites
X4741 16866 Total amino acid levels_HFD for 20 weeks [nmol/ml] Metabolites
X1603 16867 Total amino acid levels_CD [nmol/ml] Metabolites
X2175 16868 Total branched-chain amino acid levels_CDHFD [nmol/ml] Metabolites
X3489 16869 Total branched-chain amino acid levels_HFD for 20 weeks [nmol/ml] Metabolites
X2513 16870 Total branched-chain amino acid levels_CD [nmol/ml] Metabolites
X4424 16871 Total long-chain acylcarnitine_CDHFD [nmol/ml] Metabolites
X1801 16872 Total long-chain acylcarnitine_HFD for 20 weeks Metabolites
X4047 16873 Total long-chain acylcarnitine_CD [nmol/ml] Metabolites
X3006 16877 Tryptophan levels_CDHFD [nmol/ml] Metabolites
X4999 16878 Tryptophan levels_HFD for 20 weeks [nmol/ml] Metabolites
X1293 16879 Tryptophan levels_CD [nmol/ml] Metabolites
X3695 16880 Tyrosine levels_CDHFD [nmol/ml] Metabolites
X4492 16881 Tyrosine levels_HFD for 20 weeks [nmol/ml] Metabolites
X3556 16882 Tyrosine levels_CD [nmol/ml] Metabolites
X4273 10358 Body weight [g] Morphology
X3154 16883 Unknown lipid (16minRT)_CDHFD [nmol/ml] Metabolites
X3457 16884 Unknown lipid (16minRT)_HFD for 20 weeks [nmol/ml] Metabolites
X2587 16885 Unknown lipid (16minRT)_CD [nmol/ml] Metabolites
X3669 16886 Valine levels_CDHFD [nmol/ml] Metabolites
X4942 16887 Valine levels_HFD for 20 weeks [nmol/ml] Metabolites
X962 16888 Valine levels_CD [nmol/ml] Metabolites
X3786 16889 Free fatty acid (FFA)_CDHFD [z scores of umol/ml] Metabolites
X3705 16890 Free fatty acid (FFA)_HFD for 20 weeks [z scores of umol/ml] Metabolites
X4850 16891 Free fatty acid (FFA)_CD for 20 weeks [z scores of umol/ml] Metabolites
X2184 16892 Z score normalized HDL_CDHFD [umol/ml] Metabolites
X1300 16893 Z score normalized HDL_HFD for 20 weeks [umol/ml] Metabolites
X4869 16894 Z score normalized HDL_CD [umol/ml] Metabolites
X2479 16895 Weighted metabolite coexpression network, Blue module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) Metabolites
X1835 16896 Weighted metabolite coexpression network, Brown module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) Metabolites
X2086 16897 Weighted metabolite coexpression network, Green module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) Metabolites
X4878 16898 Weighted metabolite coexpression network, Turquoise module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) Metabolites
X515 16899 Weighted metabolite coexpression network, Yellow module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) Metabolites
X1023 16900 Weighted metabolite coexpression network, Blue module eigengene_HFD for 20 weeks Metabolites
X3609 16901 Weighted metabolite coexpression network, Brown module eigengene_HFD for 20 weeks Metabolites
X3439 16902 Weighted metabolite coexpression network, Green module eigengene_HFD for 20 weeks Metabolites
X4119 16903 Weighted metabolite coexpression network, Turquoise module eigengene_HFD for 20 weeks Metabolites
X2808 16904 Weighted metabolite coexpression network, Yellow module eigengene_HFD for 20 weeks Metabolites
X2786 16247 Microbiome, Actinobacteria (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X2787 16248 Microbiome, Actinobacteria (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X1877 16249 Microbiome, Actinobacteridae (subclass) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X1989 16250 Microbiome, Actinomycetales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4920 16251 Microbiome, Aerococcaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4919 16252 Microbiome, Aerococcus (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X1966 16253 Microbiome, Alistipes (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X2794 16254 Microbiome, Bacilli (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X1495 16255 Microbiome, Bacteroidales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X1496 16256 Microbiome, Bacteroidetes (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X2591 16257 Microbiome, Bacteroidetes (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X3314 16258 Microbiome, Clostridia (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X3334 16259 Microbiome, Clostridiales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4860 16260 Microbiome, Coriobacteriaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4861 16261 Microbiome, Coriobacteriales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4862 16262 Microbiome, Coriobacteridaesub (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] Microbiome
X4863 16263